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When subjected to increased workload, the heart responds metabolically by
increasing its reliance on glucose and structurally by increasing the size of myocytes.
Whether changes in metabolism regulate the structural remodeling process is unknown.
A likely candidate for a link between metabolism and growth in the heart is the
mammalian target of rapamycin (mTOR), which couples energy and nutrient metabolism
to cell growth. Recently, sustained mTOR activation has also been implicated in the
development of endoplasmic reticulum (ER) stress. We explored possible mechanisms
by which acute metabolic changes in the hemodynamically stressed heart regulate
mTOR activation, ER stress and cardiac function in the ex vivo isolated working rat
heart. Doubling the heart’s workload acutely increased rates of glucose uptake beyond
rates of glucose oxidation. The concomitant increase in glucose 6-phosphate (G6P) was
associated with mTOR activation, endoplasmic reticulum (ER) stress and impaired
vi

contractile function. Both rapamycin and metformin restored glycolytic homeostasis,
relieved ER stress and rescued contractile function. G6P and ER stress were also
downregulated with mechanical unloading of failing human hearts. Taken together, the
data support the hypothesis that metabolic remodeling precedes, triggers, and sustains
structural remodeling of the heart and implicate a critical role for G6P in load-induced
contractile dysfunction, mTOR activation and ER stress. In general terms, the
intermediary metabolism of energy providing substrates provides signals for the onset
and progression of hypertrophy and heart failure.
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CHAPTER 1: INTRODUCTION

1

1.1 Scope of the Dissertation
This thesis addresses molecular mechanisms of heart failure. Why is this
important?
First, heart failure is a leading cause of death in the United States (Roger, Go et
al. 2011). While there is a decline in the incidence of coronary artery disease, we
observe a relentless increase in mortality from heart failure. Nearly 5 million Americans
suffer from heart failure. Each year over a million patients are hospitalized because of it
and nearly 300,000 die from heart failure in the United States alone. Moreover, death
from heart failure exceeds death from all forms of cancer combined (Roger, Go et al.
2011).
Secondly, despite many advances in cardiovascular medicine, current treatment
has not seen a major drug since the advent of diuretics and neurohormonal antagonists. It
is expected that the number of heart failure patients will double in the next five years.
The development of heart failure is often preceded by cardiac growth manifested as the
hypertrophy of the cardiomyocyte. Decompensated systolic heart failure is a loss of
functional heart muscle in response to increased hemodynamic stress on the heart from
hypertension, valvular heart disease, anemia, or prior myocardial infarction. However,
the molecular mechanisms that drive the stressed heart to hypertrophy and ultimately fail
or die remain incompletely understood.
Before the stressed heart progresses into failure, it undergoes a series of
characteristic changes. The heart ‘remodels’ both metabolically and structurally.
Metabolically, hearts augment glucose uptake and oxidation, and structurally, hearts
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grow by underdoing hypertrophy. When stressed, the heart can increase its mass by up to
100% through hypertrophic remodeling (Hill and Olson 2008). Modulation of the
remodeling process is recognized as a potentially auspicious approach in the prevention
and treatment of heart failure.
The structural remodeling process has been studied extensively in an unbiased
approach using microarray gene expression profiling. With this technology, key gene
clusters involved in calcium handling proteins, sarcomeric proteins, mitochondrial
proteins, cell death, inflammation, and the extracellular matrix have been identified
(Steenman, Chen et al. 2003; Asakura and Kitakaze 2009). Unfortunately, strategies
designed to prevent apoptotic cell death, inflammation, (Sandler and Dodge 1963) and
excessive degradation of the extracellular matrix (Mann 1999) have yielded little
therapeutic benefit. Therefore, a better understanding of the remodeling process is
necessary to develop more effective treatment for heart failure.
The lab has previously demonstrated that metabolic remodeling precedes
structural remodeling in the heart (Taegtmeyer and Overturf 1988) and proposed that,
when stressed, metabolic remodeling (which is potentially reversible) regulates
functional and structural remodeling (which may be irreversible) (Taegtmeyer, Golfman
et al. 2004). I therefore set out to investigate whether the metabolic remodeling process
regulates functional and structural changes that accompany cardiac growth and explore
whether these changes are preventable.
The work presented in my dissertation provides evidence in support of the
hypothesis that metabolic remodeling precedes, triggers, and sustains structural

3

remodeling of the heart. The rationale is based on the foundation that in all eukaryotic
cells the target of rapamycin (TOR) signaling pathway couples energy and nutrient
metabolism to the execution of cell growth (Sandler, Dodge et al. 1963). Specifically, I
identify dysregulated glucose metabolism and subsequent G6P accumulation as
mediators of load-induced mTOR activation, ER stress, and contractile dysfunction. The
study highlights the importance of intermediary metabolism as a source of signals for
cardiac growth and demonstrates the potential to reduce internal work and improve
cardiac efficiency by targeting the metabolic axis in load-induced heart disease.
Understanding the mechanism and consequences of G6P-mediated mTOR
activation will help identify novel metabolic targets to reverse contractile dysfunction in
the hemodynamically stressed heart. Given the limitations of current heart failure
treatment there is an urgent need for a more targeted approach to treating the early
metabolic changes in the stressed heart. I propose that my project has taken an important
step in this direction.

1.2 Regulation of Cardiac Metabolism

In order to fully appreciate the ability for metabolic signals to activate cardiac
growth pathways, a brief review of the regulation of cardiac metabolism is needed. Like
any organ in a living organism, the mammalian heart liberates energy contained in
organic molecules to support its physiologic function (Holmes 1992). Critical steps are
phosphorylation of ADP and subsequent hydrolysis of ATP. Rates of ATP turnover in
4

the heart are greater than rates of ATP turnover in any other organ, and so are the rates
of substrate utilization and oxygen consumption (Taegtmeyer 1994). Hence, the need for
early restoration of coronary blood flow in acute coronary syndrome and myocardial
infarction.
Research on the metabolism of energy providing substrates for the heart began in
a major way when Bing performed the first coronary sinus catheterization and identified
fatty acids, glucose, and lactate as the major sources of fuel for the heart (Bing, Vandam
et al. 1947). It was appreciated early on that the heart is a metabolic ‘omnivore’, i.e. an
organ with that has the capacity to utilize multiple substrates in combination to support
contractile function (Taegtmeyer 1994). Initially, by calculating oxygen extraction ratios
and respiratory quotients (the ratio of the number of molecules of carbon dioxide
produced per oxygen taken up for a given substrate), Bing showed that the heart in the
fasted and unstressed state of the body oxidizes primarily fatty acids. Later, it was
confirmed more precisely that indeed the normal mammalian heart generates 60-90% of
its ATP from the oxidation of fatty acids and 10-40% from the oxidation of pyruvate by
glycolysis and lactate oxidation (Bing, Siegel et al. 1954; Wisneski, Gertz et al. 1987).
It has been reasoned that the healthy, unstressed heart preferentially metabolizes fatty
acids because each molecule yields significantly more reducing equivalents (H), and
hence ATP compared to glucose, lactate, or pyruvate (Table 1.1).
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Table 1.1 Comparison of energy yields from various fuels per molecule oxidized.
Adapted and expanded from The Heart: Physiology and Metabolism (Opie 1991,
page 211).

While the unstressed heart primarily oxidizes fatty acids, the increased energy
requirements of hearts subjected to high workload are met by the oxidation of
carbohydrates (Goodwin, Taylor et al. 1998). A classic explanation for this phenomenon
is based on the fact that the heart oxidizes the most efficient substrate for a given
situation (Taegtmeyer, Hems et al. 1980). Despite the higher number of reducing
equivalents per molecule, fatty acids are less oxygen-efficient (lower P/O ratio, see
Table 1.1) and require up to 40% more oxygen to produce the same amount of ATP
(Korvald, Elvenes et al. 2000). Because oxygen consumption increases linearly with
workload in the heart, when oxygen becomes a limiting factor at high workload the heart
preferentially oxidizes glycogen, glucose, and lactate (Goodwin, Taylor et al. 1998).
Similarly, it has been proposed that the poorly oxygenated fetal heart also preferentially
oxidizing glucose and lactate for this reason.
Our fundamental understanding of intermediary glucose metabolism started in
1860 with the identification of glycolysis by Pasteur (Holmes 1992). By 1937, the details
of the glycolytic pathway were discovered by Embden and Meyerhof. Later that year,
6

Krebs and Johnson demonstrated that pyruvate formed succinate and closed the loop of
the citric acid cycle (Krebs and Johnson 1937). Since then, investigators have discovered
more and more of the complexity of intermediary glucose metabolism, the multiple
metabolic fates of glucose, as well as the potential involvement of glucose in pathways
that regulate intracellular signaling in the heart. These topics will now be briefly
reviewed.
Glucose enters the cardiomyocyte down its concentration gradient from the
coronary circulation by facilitated (or carrier-mediated) diffusion through glucose
transporters (GLUT). The two major GLUTs in the heart include the insulin-independent
GLUT1 transporter found on the sarcolemma and the insulin-dependent GLUT4
transporter, which is translocated to the sarcolemma in the presence of insulin. Increases
in workload also promote glucose transporter translocation to the plasma membrane
(Wheeler, Fell et al. 1994).
The bulk of glucose taken up by the cardiomyocyte and phosphorylated enters
the glycolytic pathway and generates pyruvate, which is oxidized in the mitochondria via
the Krebs cycle. The Krebs cycle provides the reducing equivalents for the formation of
ATP under aerobic conditions. Glucose 6-phosphate can potentially enter a number of
other pathways, as well, including glycolysis, glycogen synthesis pathway, pentose
phosphate pathway, hexosamine biosynthetic pathway, and aldose reductase/polyol
pathway (Fig. 1.1). Glucose metabolism through these accessory pathways provides
some energy, maintains the biological functions of the cardiomyocyte, and plays a role
in intracellular cardiac growth signaling, as described below.
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Figure 1.1 Multiple metabolic fates of glucose 6-phosphate. Upon entry into the
cardiomyocyte, glucose can be metabolized through a number of different pathways.
Many of these pathways have been demonstrated to regulate intracellular growth
signaling either in the heart or in other organs.

Changes in the rate of glycolysis and glucose oxidation can modulate
intracellular signaling pathways by altering levels of free ADP, AMP, and the PCr:ATP
ratio in both the rodent and human heart (Neubauer 2007) (Nascimben, Ingwall et al.
2004). A hallmark of the failing heart is a reduction in the PCr:ATP ratio (Neubauer
2007), which is thought to contribute to the decline in contractile function accompanying
heart failure. On a molecular level, a reduction of the [ATP]/[AMP] ratio is known to
modulate the activity of AMP Kinase (AMPK), the ‘metabolic fuel gauge’ of the cell,
which regulates metabolic enzymes, ion channels, gene expression, and intracellular
signaling pathways of protein turnover through various phosphorylation events. Most
8

notably, AMPK phosphorylates ACC, reduces malonyl CoA, and increases fatty acid
oxidation. AMPK phosphorylation also promotes glucose transporter translocation to the
plasma membrane (Young, Li et al. 2005).
Although heart muscle lacks the enzyme glucose 6-phosphatase, glucose 6phosphate (G6P) can undergo multiple metabolic fates (Fig. 1.1). G6P can be converted
into UDP-N-acetylglucosamine (UDPGlcNac) by the enzyme glutamine:fructose-6phosphate-amidotransferase (GFAT), the rate-limiting enzyme of the hexosamine
biosynthetic pathway. UDPGlcNac serves as the substrate for O-GlcNacylation of
proteins by the enzyme O-GlcNac transferase (OGT). Like phosphorylation reactions,
post-translational modification of proteins and transcription factors by O-GlcNacylation
holds potential to regulate a number of intracellular signaling pathways (McClain 2002).
Indeed, both gene expression of the rate limiting enzyme GFAT (Young, Yan et al.
2007) and O-linked –N-acetylglucosamine transferase are known to be elevated in
mouse models of heart failure (Watson, Facundo et al. 2010).
The pentose phosphate pathway provides an additional avenue for glucose upon
entry into the cardiomyocyte (Fig 1.1). Our laboratory has previously demonstrated that
up to 20% of glucose taken up by the heart enters the pentose phosphate pathway
(Goodwin, Cohen et al. 2001). The pathway is divided into the oxidative and nonoxidative arms (Horecker and Mehler 1955). The oxidative arm consumes G 6-P using
glucose 6-phosphate dehydrogenase (G6PD). The non-oxidative arm of the pentose
phosphate pathway produces xylulose-5-phosphate, an important building block for
nucleic acid synthesis but less well appreciated for its ability to induce the expression of
metabolic genes in the liver such as pyruvate kinase (Nishimura and Uyeda 1995;
9

Doiron, Cuif et al. 1996). G6PD enzyme activity is upregulated in cardiac hypertrophy
(Zimmer 1992). The significance of this may relate to increased ribose formation and/or
modulation of oxidative stress.
G6P can also be enzymatically converted to sorbitol by aldose reductase with a
concomitant decrease in NADPH, as well (Hwang, Kaneko et al. 2004). NADPH is a
required cofactor for the regeneration of the reduced form of the anti-oxidant
glutathione, and its depletion would exacerbate intracellular oxidative stress.
Intracellular oxidative stress triggers a number of intracellular signaling pathways
including those involved in growth signaling (Alexander, Cai et al. 2010). When present
in excess, glucose is also converted to glycogen by the enzyme glycogen synthase.
Glycogen synthase is phosphorylated by glycogen synthase kinase 3β (GSK-3β) which
itself is a regulatory kinase that modulates cardiac growth (Haq, Choukroun et al. 2000).
It is conceivable that this kinase plays a dual role in modulating both glucose
metabolism in the heart and cardiac growth, as well. I will explore the role of
intermediary glucose metabolites and assess whether these accessory pathways regulate
cardiac growth in the stressed heart. Changes in glucose metabolism known to occur
with cardiac hypertrophy are summarized in (Fig. 1.2). Interestingly, the same changes
are present in the unloaded, atrophied heart (Depre, Shipley et al. 1998) (Doenst,
Goodwin et al. 2001).
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Figure 1.2 Changes in glucose metabolism in the pressure-overload induced
hypertrophied heart. Pathways marked in green have been shown to increase,
pathways marked in red have been shown to decrease, and pathways marked in blue
have been shown to not change in the hypertrophied heart. Black arrows, boxes, and text
represent pathways that have yet to be extensively studied in the hypertrophied heart.
GFAT, glutamine fructose-6-phosphate amidotransferase; GLUT, glucose transporter;
LDH, lactate dehydrogenase; ME, malic enzyme; NADH, reduced nicotinamide adenine
dinucleotide; OMC, oxoglutarate-malate carrier; PC, pyruvate carboxylase; MCT,
monocarboxylate transporter. Modified from Kolwicz and Tian Cardiovascular
Research 2011. Reprinted with permission from Oxford University Press.
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1.3 Structural and Functional Responses of the Heart to Altered Hemodynamic
Load

Development of Cardiac Hypertrophy:
A wide variety of both physiological and pathological stimuli can promote
cardiac growth. Physiological cardiac hypertrophy (growth) occurs during postnatal
growth, pregnancy, and with prolonged vigorous exercise. Pathological cardiac
hypertrophy is induced by cardiac injury, hypertension, or neurohormal stimulation (Fig.
1.3). In the nineteenth century, cardiac growth was first thought to merely represent a
step in the development of heart failure when Sir William Osler characterized it as a
phenomenon that “takes place slowly and results from degeneration and weakening of
the heart muscle” (page 98). (Osler W. The Principles and Practice of Medicine. New
York: Appleton, 1892.)
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Figure 1.3 Plasticity of the Heart. The healthy human heart structurally remodels in
response to both increases and decreases in load. A reduction in load leads to atrophy
and an increase in load leads to hypertrophy. Sustained increases in pathological load
are known to lead to heart failure and ventricular arrythmias (Hill and Olsen, NEJM
2008). Reprinted with permission from Massachusetts Medical Society.

Nearly a century later, data from the Framingham Heart Study recognized left
ventricular hypertrophy as a true risk factor for heart failure and arrhythmias (Levy,
Garrison et al. 1990; Koren, Devereux et al. 1991). Why does it occur? According to the
law of LaPlace:
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wall tension = (pressure) x (radius)/(wall thickness)
Accordingly, increased wall thickness in the heart reduces ventricular wall
tension in hearts subjected to high workload (Sandler and Dodge 1963; Grossman, Jones
et al. 1975). However, cardiac hypertrophy secondary to valvular heart disease is
associated with contractile dysfunction irrespective of the degree of valvular damage
(Gunther and Grossman 1979) (Huber, Grimm et al. 1981) (Krayenbuehl, Hess et al.
1988) suggesting that its development may not follow as linear of a pattern as the law of
LaPlace would suggest. Is hypertrophy necessary to compensate for increased cardiac
work? In preclinical studies, contractile function is preserved in hearts subjected to high
workload and treated with small molecular inhibitors of intracellular growth signaling
pathways (Hill, Karimi et al. 2000), suggesting that cardiac growth may not be
necessary. It remains difficult to ascertain whether cardiac growth is initially a necessary
adaptive response in the stressed heart or not.
On a molecular level, the heart has different mechanisms to respond to acute and
sustained increases in hemodynamic load. When subjected to an acute increase in
workload, changes in cardiac metabolism occur instantaneously, as discussed above.
Similarly, even acute changes in workload trigger changes in the post-translational
modification of proteins, as well. Most notably, increased workload regulates the
activation of membrane-bound receptors such as G-protein coupled receptors leading to
downstream changes in the protein phosphorylation and activation of growth signaling
pathways (Molkentin and Dorn 2001). Ultimately, sustained increases in workload and
activation of these signaling pathways lead to changes in gene expression. Previous
members of the lab have reviewed the transcriptional changes in metabolic genes
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(GLUT1, GLUT4, PPAR-alpha,PDK2, MCAD, ACC) and contractile protein (myosin
heavy chain) isoforms, in the stressed heart (Rajabi, Kassiotis et al. 2007).
Modulation of myocardial growth and hypertrophy without adversely affecting
contractile function is increasingly recognized as a potentially auspicious approach in the
prevention and treatment of heart failure. A better understanding of the intracellular
signaling cascades that drive the hypertrophic process are necessary before this will be
possible. This begs the question: which signals and intracellular signaling pathways
drive the normal heart to hypertrophy and ultimately fail? Can they be targeted?
Molkentin et al have extensively reviewed the highly coordinated manner by which a
number of signaling cascades interact to regulate cardiac growth signaling (Molkentin
and Dorn 2001; Dorn and Force 2005). However, only the mammalian target of
rapamycin (mTOR) signaling pathway is known to be both activated in the heart in
response to increased workload and responsive to changes in a cell’s metabolic milieu. I,
therefore, focused our attention on studying whether the metabolic changes known to
occur in hearts subjected to increased workload regulate mTOR activation in the stressed
heart.

Regression of Cardiac Hypertrophy:
A number of studies have demonstrated that regression of left ventricular
hypertrophy improves outcome in patients with cardiovascular disease. In the Heart
Outcomes Prevention Evaluation (HOPE) trial, patients with either known high-risk
vascular disease or diabetes and at least one additional cardiovascular risk factor
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(hypertension, dyslipidemia, cigarette use, microalbuminuria) were randomly assigned to
receive either an angiotensin converting enzyme (ACE) inhibitor or placebo daily for 2.5
years (Yusuf, Sleight et al. 2000). Up to a decade later, analyses from the study
identified that inhibition or even regression of cardiac hypertrophy by ACE inhibitor
therapy lowered the risk for several cardiovascular endpoints including death and
progression to heart failure, whereas persistence of cardiac hypertrophy (despite similar
blood pressure changes) predicted an adverse outcome (Mathew, Sleight et al. 2001).
Mechanical reduction of load in patients with heart failure also improves
cardiovascular hemodynamics, functional status, and quality of life. In the Randomized
Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure
(REMATCH) study, patients with New York Heart Association Class III or IV heart
failure were randomized to either optimal medical management or implantation of a left
ventricular device (Rose, Gelijns et al. 2001) (Fig. 1.4). At the time of final analysis,
LVAD implantation was associated with a forty eight percent reduction in the risk of
death from any cause and improvement in quality of life compared to optimal medical
therapy.
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Figure 1.4 Components of an LVAD. The LVAD mechanically reduces the
load on failing heart. Circulating blood enters the LVAD from the left ventricle
through the inflow cannula. The prosthetic left ventricular then pumps the
blood through the outflow cannula and into the (ascending) aorta. The pumping
chamber is placed within the abdominal wall or peritoneal cavity. A
percutaneous drive exits the skin and connects the device to external battery
packs worn on shoulder holsters and a system controller worn on the belt.
Image reprinted with permission from Massachusetts Medical Society (Rose,
Gelijns et al. 2001).
The effects of LVAD implantation on cardiac metabolism have been investigated
extensively at the transcriptional and post-translatoinal levels (Razeghi, Myers et al.
2002) (Margulies, Matiwala et al. 2005). Previous studies in our lab have observed a
trend for decreased myocardial glycogen content in failing human hearts after
mechanical unloading (Razeghi and Taegtmeyer 2004) and more recently, proteomic
analysis has revealed an upregulation of proteins involved in glycolysis, energy, and
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oxidative metabolism in LVAD supported patients.(de Weger, Schipper et al. 2011)
Taken together, these data suggest improved metabolic capacity with mechanical
unloading with LVAD implantation. This conclusion is supported by reports that have
suggested improvements in respiratory capacity in mitochondrial isolated from hearts of
patients supported by an LVAD (Lee, Doliba et al. 1998).

1.4 mTOR Signaling Pathway

In mammalian tissue, mTOR links nutrient availability to growth in muscle,
adipose, liver, and hypothalamus (Howell and Manning 2011). Cardiac growth can occur
directly in response to nutrient availability in the Burmese python, which exhibits a 40%
increase in ventricular mass within 48 hours of consuming a large meal (Andersen,
Rourke et al. 2005; Riquelme, Magida et al. 2011) and I therefore wondered whether it
occurs in the stressed heart in an mTOR-dependent manner, as well.
Load-induced protein synthesis and cardiac growth is regulated mTOR, a highly
conserved member of the phosphatidylinositol 3 kinase (PI3 kinase) superfamily that
regulates cell growth by initiating protein translation and by inducing ribosomal
biogenesis (Crespo and Hall 2002) (Rohde, Heitman et al. 2001). Research on mTOR
began when the drug rapamycin, an inhibitor of T cell proliferation and potent
immunosuppressant, was serendipitously isolated from a strain of Streptomyces
hygroscopius from soil collected in Rapa-Nui (Easter Island) in the 1970’s (Crespo and
Hall 2002). Rapamycin is now an FDA-approved immunosuppressant for preventing
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graft rejection or re-stenosis after angioplasty, and rapamycin is actively being used in a
number of cancer clinical trials to reduce tumor growth (Garza, Aude et al. 2002)
(Huang and Houghton 2003). Whether in fungi, T-cells, vascular smooth muscle or
cancer cells, the primary action of rapamycin is inhibition of cell growth. The protein
responsible for rapamycin action was first identified in yeast and called TOR (target of
rapamycin) (Kunz, Henriquez et al. 1993). By analyzing gene expression in yeast cells
exposed to rapamycin, it was discovered that TOR mediates protein synthesis and was
regulated by nutrient availability in yeast (Cardenas, Cutler et al. 1999). Indeed, in
eukaryotic organisms the ability to alter growth according to nutrient availability is
essential for survival.
Studies undertaken to elucidate the mechanism by which rapamycin inhibits
mTOR revealed that the mTOR kinase actually nucleates two major protein complexes –
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (Schmelzle and Hall
2000). mTOR complex 1 (mTORC1) contains the scaffolding protein regulatoryassociated protein of mTOR (raptor) as well as mammalian lethal with Sec13 protein 8
(mLST8), the proline-rich Akt substrate 40 kDa (PRAS40), and DEP-domain-containing
mTOR-interacting protein (Deptor) and regulates cell growth. mTOR complex
(mTORC2) consists of mLST8, the scaffolding protein raptor-independent companion of
TOR (rictor), mSIN1 proteins, and the protein observed with rictor (Protor) and
cytoskeleton regulation and cell survival (Laplante and Sabatini 2009). The components
of each respective protein complex are necessary for either upstream regulation,
complex formation, or downstream signal activation and function. Most notably,
however, mTORC2 is distinguished from mTORC1 by its resistance to inhibition with
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acute rapamycin treatment (Sarbassov, Ali et al. 2006). In fact, only prolonged
rapamycin treatment (an important consideration for my experiments, see Chapter 3)
inhibits mTORC2 complex assembly and reduces the levels of mTORC2 below those
needed to maintain downstream Akt signaling both in vitro (Sarbassov, Ali et al. 2006),
and in samples from patients with acute myeloid leukemia (Zeng, Sarbassov dos et al.
2007) (Fig. 1.5). mTORC2 is also known to activate PKCalpha to regulate actin
reorganization and SGK1 to regulate FOXO (Powell and Delgoffe 2010), however the
regulation of these proteins by rapamycin has yet to be studied. Our insight into
upstream activators of mTORC2 is limited, as well. However, a wealth of information
exists on both upstream activators of mTORC1 and downstream consequences, which
will now be reviewed.
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In the unstressed heart, mTOR and its downstream targets, 4EBP1 and p70S6K
(S6K1), are inhibited by the upstream protein Ras homolog enriched in brain (Rheb).
Rheb is a small GTPase that requires binding of GTP to interact with and activate mTOR
(Long, Ortiz-Vega et al. 2005). Upstream of Rheb is the tuberous sclerosis complex
(TSC), which is composed of the proteins TSC1 and TSC2 (Inoki, Corradetti et al.
2005). TSC2 is the GTPase-activating protein (GAP) for Rheb and when bound by
TSC1, it promotes the conversion of Rheb-GTP to Rheb-GDP, thereby inhibiting mTOR
(Inoki, Li et al. 2003). Therefore, differential phosphorylation of TSC2 regulates
mTORC1 activation (Huang and Manning 2008).
Growth factors, branched chain amino acids, reactive oxygen species (ROS), and
genotoxic stress are all upstream regulators of mTORC1 (Sengupta, Peterson et al.
2010). Growth factors such as insulin and IGF-1 activate mTORC1 by differentially
phosphorylating TSC2 to suppress its GAP activity on Rheb in a PI3K-dependent
manner (Tee, Anjum et al. 2003) and amino acids activate mTORC1 by promoting
mTOR interaction with lysosomal Rheb-GTP (Sancak, Peterson et al. 2008) (Sancak,
Bar-Peled et al. 2010) whereas ROS and genotoxic stress inhibit mTOR by stabilizing
the TSC complex and TSC2’s GAP activity on Rheb (Budanov and Karin 2008;
Alexander, Cai et al. 2010). I, therefore, felt it was plausible that metabolic regulation of
mTOR activation in the heart also occurred in a TSC or Rheb-dependent manner.
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1.5 Endoplasmic Reticulum Stress

A consequence of sustained activation of mTOR is increased and uncontrolled
protein synthesis leading to endoplasmic reticulum (ER) stress. In the unstressed
cardiomyocyte, proteins synthesized in the rough endoplasmic reticulum are efficiently
folded. Molecular chaperones located within the ER facilitate this process by identifying
hydrophobic regions of misfolded or unfolded proteins and refolding them into
functioning proteins in order to prevent toxic protein aggregate formation (Ron and
Walter 2007). The chaperone protein glucose-regulated protein 78 (GRP78) also serves
as a gauge for sensing protein homeostasis within the endoplasmic reticulum. When the
concentration of misfolded or unfolded proteins is low, GRP78 remains bound to the
three ER proximal effectors – PKR-like ER kinase (PERK), insolitol-requiring enzyme-1
(IRE-1), and activating transcription factor-6 (ATF6). When bound by GRP78, these
proximal effectors remain inactive. When subjected to hemodynamic stress (continued
pumping against high workload), mTOR activation promotes cardiac growth by
increasing rates of protein synthesis. Up to one third of all proteins synthesized in the
cardiomyocyte are shuttled through the endoplasmic reticulum (Blobel 2000). When
hypertrophic stimuli are sustained, rates of protein synthesis exceed the protein folding
capacity of the ER leading to the accumulation of unfolded and misfolded proteins
beyond the ER’s capacity to cope with the load (Okada, Minamino et al. 2004;
Glembotski 2008). The hydrophobic regions of unfolded and misfolded proteins attract
GRP78. GRP78 translocation from the luminal surface of IRE-1, ATF6, and PERK
activates all three proximal effectors. One of the earliest consequences of proximal
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effector activation is the transcriptional activation of ER stress-response genes including
chaperone proteins (GRP78, GRP94), disulfide isomerases (ER protein 72, ERp72), and
calcium binding proteins (calreticulin). Interestingly, the promoter site of most ER stress
response genes has an ER stress response element, suggesting that transcriptional
induction is highly conserved (Thuerauf, Hoover et al. 2001). Increased expression of
these genes enhances the protein folding capacity of the ER. Moreover, if its
transcriptional activation is sufficient to alleviate the acute increase in ER stress, excess
GRP78 once again binds the proximal effectors and signals the resolution of the ER
stress response.
In both human and animal studies, contractile dysfunction in the hypertrophic
and failing heart has been linked to elevated glucose uptake (Taegtmeyer and Overturf
1988) (Zhang, Duncker et al. 1995) (Bishop and Altschuld 1970) in an insulinindependent manner (Allard, Wambolt et al. 2000). It is also known that normal
contractile function of the cardiomyocyte requires proper protein folding. However,
whether elevated glucose uptake is associated with contractile dysfunction in hearts
subjected to high workload as a result of improper protein folding has yet to be studied.
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Figure 1.6 Endoplasmic Reticulum (ER) Stress Response. When the protein
folding capacity of the ER is exceeded, the ER stress response is activated. Adapted
from Glembotski JMCC 2008. Reprinted with permission from Elsevier Publishing
Company.
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If the ER stress response is sustained, PERK activation inhibits the activation of
the protein translational machinery via the phosphorylation of eukaryotic initiation factor
2 α (eIF2α) and IRE1 activation ultimately leads to apoptosis via the activation of JNK
and caspase-12.
Ischemia is a known activator of the ER stress response. Mouse hearts subjected
to ischemia and reperfusion ex vivo demonstrate increased GRP78 expression as do
myocytes surrounding the infarct zone in mice subjected to myocardial infarction in vivo
(Thuerauf, Marcinko et al. 2006). The mechanism is thought to involve AMPK
activation (Terai, Hiramoto et al. 2005) and lead to the activation of autophagy-mediated
cell death (Takagi, Matsui et al. 2007). The ER stress response is also activated in
hypertrophied and failing mouse hearts that have been subjected to increased workload
by transverse aortic constriction (Okada, Minamino et al. 2004). Whether load-induced
mTOR activation, ER stress and contractile dysfunction are metabolically regulated in
the heart remains unknown.
Systemic metabolic disorders such as diabetes are associated with ER stress in
skeletal muscle, liver, and adipocytes (Hotamisligil 2010) (Eizirik, Cardozo et al. 2008).
Indeed, changes in glucose or fatty acid metabolism in vitro regulate the ER stress
response. Whether changes in cardiac metabolism regulate (or are regulated by) ER
stress remain to be investigated. Because chemical chaperone treatment has been shown
to alleviate ER stress and correct glucose homeostasis in mouse models of diabetes
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(Ozcan, Yilmaz et al. 2006), it is plausible that it holds great promise in targeting heart
disease, as well.
The consequences of ER stress on cardiac function and metabolism form the
second part of my thesis. They have led us to speculate that relief of ER stress improves
metabolism and efficiency of the heart.
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CHAPTER 2: MATERIALS AND METHODS
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2.1 Rationale for Methods Used and Overall Strategy

The structural and functional response to increased workload has been extensively
studied in the murine transverse aortic constriction (TAC) model (Rockman, Ross et al.
1991). How the metabolic responses to increased workload may regulate these changes
has yet to be investigated. In order to answer this question systematically we used three
different models – C57BL/6J mouse hearts subjected to increased workload in vivo by
TAC, Sprague-Dawley rat hearts subjected to increased workload ex vivo using the
isolated working heart apparatus, and left ventricular tissue samples from human heart
failure patients before and after implantation of a left ventricular assist device (LVAD).
First, in studies initiated in the laboratory of our collaborator Bijoy Kundu at the
University of Virginia Medical School, in vivo FDG-PET and MRI were performed
simultaneously in mice subjected to TAC for upto four weeks to serially image changes
in metabolism, structure and function in response to increased cardiac workload. Using
this model, it was established that metabolic remodeling (enhanced glucose uptake) and
contractile dysfunction precede structural remodeling (growth and dilation of the left
ventricle) of the heart when subjected to increased workload. Second, we systematically
manipulated workload and substrate supply individually used the isolated working rat
heart ex vivo to elucidate the mechanisms for the observed phenomena in vivo. The
isolated working rat heart permitted a dynamic minute-by-minute assessment of
metabolism and function and allowed for assessment of intracellular metabolites and
activation of relevant signaling pathways at the end of the perfusion. The ex vivo isolated
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working heart model was also chosen because it gave us complete control over
workload, substrate concentration and hormone supply. Third, we analyzed left
ventricular tissue from failing human heart muscle before and after mechanical
unloading with a left ventricular assist device to correlate our findings to the failing
human heart, as well. Thus, in contrast to the prevailing strategies (from the bedside to
the bench) we went from the bench to the bedside to test whether findings in ex vivo
models are relevant for the failing heart in vivo. The following materials and methods
were required to carry out these studies.

2.2 Materials

2.2.1 Rodent Experiments
2.2.1.1 Mice
For our in vivo imaging studies, male C57BL/6J mice (8-9 weeks of age)
obtained from Charles River Laboratories (Raleigh, NC) were subjected to sham
operation or transverse aortic constriction (TAC) to induce pressure-overload
hypertrophy by our collaborators at The University of Virginia Medical School using
methods previously described (Liao, Takashima et al. 2003). During each imaging
protocol, left ventricular pressure measurements were performed using a Mikro-tip
Catheter Transducer (Model SPR-671, Size 1.4F, Millar Instruments Inc., Houston, TX)
connected to Millar and PowerLab hardware and ADI Software (AD Instruments Inc.,
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Colorado Springs, CO). Throughout the experiment heart rate, respiration, and body
temperature were recorded with a physiological recorder (SA Instruments, Inc., model
1025L, Stony Brook, NY), and the ECG were monitored (Blue Sensor, Ambu Inc., Glen
Burnie, MD) and stored for further analysis later. The SAI 1025L was also used to
maintain the animal’s core body temperature at 37oC. Positron Emission Tomography
(PET) with the fluorinated glucose tracer analogue 2-deoxy-2-[18F] fluoro-D-glucose and
Magnetic Resonance Imaging (MRI) were sequentially performed in anesthetized
animals. PET imaging was performed in a Focus 120 micro PET scanner (Siemens
Molecular Imaging Inc., Knoxville, TN) to assess changes in metabolism. 150-200 µL of
18.5-37 MBq FDG solution (IBA Molecular, Sterling VA) was injected intravenously
into the mice over a period of one minute prior to imaging. Arterial blood samples were
used for input function estimation. Mice were also imaged using a 7T Bruker-Siemens
Clinscan MRI system for structural and functional analyses of the heart. The MR images
were analyzed using the ARGUS software package (Siemens Medical Systems,
Erlangen, Germany) for left ventricular end systolic volume (LVESV) and left
ventricular end diastolic volume (LVEDV) while left ventricular ejection fraction
(LVEF) was computed from the traced borders.

2.2.1.2 Rats
For our ex vivo studies, male Sprague-Dawley rats (387 ± 11g) were obtained
from Harlan Laboratories (Indianapolis, IN) and housed in the Animal Care Center of
The University of Texas Medical School at Houston under controlled conditions (23 ±
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1oC; 12-h light/12-h dark cycle) prior to experimentation. The animals received standard
laboratory chow (LabDiet® Rodent Diet 5001 containing as a percentage of total
calories: 28 % protein, 60 % carbohydrate and 12 % fats) and water ad libitum and were
given at least 48 hours to acclimatize to the facility before they were used in
experiments.
Through the course of this project, two subsets of rats received pharmacological
agents before they were sacrificed. The first subset of rats received either the mTOR
inhibitor rapamycin (4 mg/kg/d) or vehicle control (propylene glycol) by oral gavage for
7 days prior to the experiments. We have previously shown that the timing, dose, and
delivery of the drug is effective in inhibiting mTOR in the heart (Sharma, Guthrie et al.
2007). The second subset received either metformin (250 mg/kg/day or 500 mg/kg/day)
or vehicle control (saline) intraperitoneally for 7 days prior to sacrifice. Others have
shown before us that the delivery of metformin by IP injection activates AMPK in the
heart (Gundewar, Calvert et al. 2009; Benes, Kazdova et al. 2011). Prior to perfusion, all
animals were anesthetized with chloral hydrate (300 mg/kg/kg).
Reflexes were tested in all four limbs prior to incision to ensure sufficient sedation.
A midline incision was then made to each animal and heparin (200U) was injected
directly into the inferior vena cava immediately before opening the thoracic cavity to
ensure proper anticoagulation. Hearts were then quickly removed and transferred into
ice-cold saline. After cannulation, hearts were perfused in the working mode as
described before (Taegtmeyer, Hems et al. 1980) and as will be described later.
At the conclusion of each perfusion protocol, hearts were freeze-clamped while
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still beating with aluminum tongs cooled in liquid nitrogen (Wollenberger and Schulze
1961). A portion of frozen heart tissue was used for dry weight calculations and the
remainder used for molecular analyses.

2.2.2. Left Ventricular Tissue Samples from Heart Failure Patients
Myocardial biopsy samples were obtained from the hearts of 11 non-diabetic
patients with idiopathic dilated cardiomyopathy referred to the Texas Heart Institute (Dr.
O.H. Frazier) for heart transplantation at the time of placement of left ventricular assist
device (LVAD) and at the time of removal after a mean duration of 254±63 days on
mechanical support. Table 2.1 provides further details on the patients assessed in this
study. Because mTOR is known to be activated by insulin and many diabetic patients are
hyperinsulinemic, only non-diabetic patients were studied. A reduction in LVEDD in
each patient was used to confirm unloading.
Tissue from the left ventricular apex was obtained during LVAD implantation
and again from the same heart during explantation when each patient received a heart
transplant. Tissue samples were immediately frozen in liquid nitrogen and stored at 80oC for metabolic and molecular analyses.
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Table 2.1 Clinical Data for 11 Patients with Idiopathic Dilated Cardiomyopathy.
Abbreviations: LVAD = left ventricular assist device, LVEDD = left ventricular end
diastolic dimension, EF = ejection fraction. Data are presented as the mean ± SEM.

2.2.3. Perfusion Apparatus for the Isolated Working Heart
The perfusion apparatus used in this project was nearly identical to the one
previously described (Taegtmeyer, Hems et al. 1980). In a modification of the method
developed by Taegtmeyer et al., in this project the apparatus was assembled in the nonrecirculating mode to prevent the accumulation of lactate, the end product of glycolysis
and a carbohydrate substrate that would confound our data.
The glassware used to assemble the perfusion apparatus was designed by Dr.
Heinrich Taegtmeyer and made by Mr. Peter Brooks (Ducklington, Oxon, England). The
apparatus (Fig. 2.1) consisted of (a) A reservoir containing fresh perfusate, (b) Watson
Marlow 505S peristaltic pump (Watson Marlow Wilmington, MA), which circulated the
perfusate through the apparatus, (c) 5 µm Millipore filter (Millipore Billerica, MA),
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which filtered out any debris that may have precipitated out of the perfusate, (d) multibulb oxygenator (connected to an external oxygen tank) (e) oxygen sensor, (f) perfusion
chamber, which housed the cannulated heart, (g) compliance chamber, (h) aortic
overflow reservoir, (i) coronary overflow reservoir, (j) Langendorff reservoir, and (k)
reservoir for metabolized perfusate. Each piece of glassware was taken down,
disconnected from its tubing and submerged in Chromerge (Sigma Aldrich, St Louis,
MO) at the end of the day daily to prevent protein and bacterial contamination of the
glassware (Fanburg, Posner Biochim Biophys Acta1969) (Fig. 2.1).
The glassware was water-jacketed and circulated with water in the opposite
direction of the perfusate at a constant temperature of 37o by a C10 immersion circulator
(Haake GmbH, Karlsruhe, Germany). The water temperature was measured using a YSI
Tele-thermometer (YSI, Yellow Springs, Ohio). The perfusate circulated between pieces
of glassware through PVC tubing (VWR, West Chester, PA), which was replaced daily.
The PVC tubing and glassware were flushed out with 4L of ddH2O in between
experiments.
Aortic pressures were continuously registered throughout each perfusion with a
Millar Mikro-Tip Catheter Transducer (Model #SPR-524, size 2.5F) attached to a Millar
Transducer Balance, model TBC-500 (Millar Instruments Co, Houston, TX). The signal
was transmitted to a MacLab/4e AD instrument and recorded, stored, and analyzed using
MacLab software, chart v3.3.5 (AD Instruments Inc., Colorado Springs, CO). The
following parameters were recorded: heart rate, systolic and diastolic pressures, and
mean aortic pressure.
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Figure 2.1 Modification of perfusion apparatus developed by Taegtmeyer,
Hems and Krebs. The apparatus consisted of a (a) reservoir containing fresh
perfusate, (b) Watson Marlow 505S peristaltic pump, (c) 5 µm Millipore filter, (d)
multi-bulb oxygenator, (e) oxygen sensor, (f) perfusion chamber, (g) compliance
chamber, (h) aortic overflow reservoir, (i) coronary overflow reservoir, (j) Langendorff
reservoir, and (k) reservoir for metabolized perfusate.

2.2.4 Liquid Scintillation Counter for Determination of Radioactivity
Ultima Gold liquid scintillation cocktail (Perkin Elmer, Waltham, MA) was
added to coronary effluent samples in a 25 mL glass or PVC scintillation vial and read in
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a Packard Model 2200 liquid scintillation counter (Packard Instruments, Warrenville, IL)
to measure radioactivity. Radioactive decay was measured by the scintillation counter in
counts per minute, which was then converted into disintegrations per minute. Samples
were stored in the dark overnight prior to reading to correct for liquid sctintillation
cocktail autoilluminescence. Both [U-14C]glucose and [2-3H]glucose were obtained from
Perkin Elmer (Waltham, MA).

2.2.5 Spectrophotometer for Assessment of Intracellular Metabolite Content
All metabolite analyses were performed on a Shimadzu UV1600 UV-visible
Spectrophotometer (Tokyo, Japan). Enzymes necessary for metabolite analyses,
including hexokinase and glucose 6-phosphate dehydrogenase used for measuring
glucose 6-phosphate, were purchased from Sigma Aldrich (St. Louis, MO).

2.2.6 Western Blotting Apparatus and Sources of Antibodies
Mini-PROTEAN Tetra Cell electrophoresis system and Trans-Blot SD Semi-Dry
Transfer Cell (Bio-Rad, Hercules, CA) were used to separate proteins from heart lysates
and transfer them onto a nitrocellulose membrane (GE Healthcare Life Sciences,
Pittsburgh, PA). Proteins were detected using Amersham ECL Plus, also purchased from
GE Healthcare Life Sciences.
Antibodies for PI3K, AKT 1/2, TSC2, mTOR, RAPTOR, p70S6K1, 4EBP1, AMP
kinase, Acetyl CoA Carboxylase (ACC), phospho-PI3K p85 (Tyr458)/p55 (Tyr199)
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phospho-Akt1/2 (Ser473), phospho-mTOR (Ser2448), phospho-p70S6K (Thr389),
phospho-4EBP1 (Thr70), (phospho-AMPKinase (Thr172), phospho-ACC (Ser79),
phospho-TSC2 (Ser 939), and phospho-RAPTOR (Ser 792) were obtained from Cell
Signaling (Beverly, MA). Antibody for glucose-regulated protein 78 (GRP78), glucoseregulated protein 94 (GRP94), and ER protein 72 (ERp72) were purchased from Enzo
Life Sciences (Plymouth Meeting, PA) and GADD153 was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). GAPDH was used to normalize for protein loading
(Research Diagnostics, NJ).

2.2.7 Sequence Analyzer for Quantitatve RT-PCR
Absolute quantification of gene expression was completed using an ABI Prism
7000 Sequence Detection System (Foster City, CA). The ABI 7000 calculates absolute
transcript numbers by comparing the number of cycles necessary to meet a fluorescence
threshold in the sample to the number of cycles needed in standard amounts of RNA
over a 105 range (standard curve method). Taqman probe chemistry was utilized to
generate fluorescence by uncoupling the fluorogenic dye molecule and the quencher
moeity found on a nucleic acid probe by Taq polymerase during each PCR cycle.

2.2.8 Miscellaneous Equipment
Revco -80oC freezer (Thermo Scientific, Asheville, NC) and -20oC freezer
(Sanyo Scientific, Bensenville, IL) for sample and reagent storage, NanoDrop ND-1000
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spectrophotometer (Nanodrop Technologies, Wilmington, DE) for RNA concentration
assessment, Polytron tissue homogenizer (Brinkman Instruments, Westbury, NY), Ohaus
AS120 scale (Florham Park, NJ), Eppendorf desktop centrifuge Model 5415C
(Hamburg, Germany), Isotemp shaking water bath (Fisher Scientific, Waltham, MA),
and 2EG gravity convection oven (Precision Scientific, Chicago, IL) for dry heart
sample preparation.

2.3

Methods

2.3.1 PET and MRI Imaging
Male C57BL/6J mice (8-9 weeks of age) were subjected to sham operation or
transverse aortic constriction (TAC) to induce pressure-overload hypertrophy and
housed in a 12 h light/12 h dark cycle and given standard laboratory chow and water ad
libitum at The University of Virginia Medical School. Mice were serially imaged 1 day,
2 weeks, and 4 weeks after either sham or TAC surgery by the Kundu lab at the
University of Virginia Medical School. Prior to imaging, animals were fasted overnight
with access to water. All experiments were performed in compliance with the Guide for
the Care and Use of Laboratory Animals, published by the National Institutes of Health
and were conducted under protocols approved by the Animal Care and Use Committee
at the University of Virginia. On the day of imaging, each mouse was anesthetized with
3% Isoflurane and maintained at 1-2% Isolflurane. A Mikro-tip Catheter Transducer was
then placed in the right carotid artery under stereo-magnification and advanced through
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the aorta until the tip was positioned in the left ventricle to make left ventricular pressure
measurements.

Heart rate and cardiac pressure were continuously monitored

throughout. Body temperature was maintained at 37oC with a warming blanket.
Positron Emission Tomography (PET) with [18F] FDG and Magnetic Resonance
Imaging (MRI) were sequentially performed in anesthetized animals. PET imaging was
performed in a Focus 120 micro PET scanner (Siemens Molecular Imaging Inc.,
Knoxville, TN) to assess changes in metabolism. The protocol was initiated by injecting
150-200 µL of 18.5-37 MBq FDG solution intravenously over a period of one minute.
The net FDG influx constant, Ki (1/min), was measured over a period of 4 weeks.
Determination of Ki is considered a robust index of glucose transport and
phosphorylation (Nguyen, Mossberg et al. 1990). Throughout the procedure heart rate,
respiration, and body temperature were recorded with a physiological recorder (SA
Instruments, Inc., model 1025L, Stony Brook, NY), and the ECG was monitored (Blue
Sensor, Ambu Inc., Glen Burnie, MD). All of the signals were sent to a single SA
Instruments software interface, which was configured to trigger data acquisition based
on the ECG. The SAI 1025L was also used to maintain the animal’s core body
temperature at 37oC.
Mice were also imaged using a 7T Bruker-Siemens Clinscan MRI system for
structural and functional analyses of the heart. After once again being anesthetized, the
mouse was placed prone inside the radiofrequency coil, and the ECG leads were
connected to an ECG monitoring module (SA Instruments, Inc., Stony Brook, NY). An
ECG-triggered, 2D cine gradient echo pulse sequence was used (Berr, Roy et al. 2005)
with a slice thickness of 1 mm and a zero-filled, in-plane resolution of 100x100 µm2.
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During each session, the entire LV was imaged with 6-7 contiguous short-axis slices.
The MR images were analyzed using the ARGUS software package (Siemens Medical
Systems, Erlangen, Germany) for LVESV, LVEDV, and LVEF was computed from the
traced borders. Epicardial contours were also traced at the end-diastolic and end-systolic
phases to compute LV mass (Vinnakota and Bassingthwaighte 2004). This was divided
by the body weight to obtain the HW/BW ratios.

2.3.2. Isolated Working Rat Heart Perfusions
Isolated hearts were perfused using the isolated working heart apparatus, as
described previously (Taegtmeyer, Hems et al. 1980; Goodwin, Taylor et al. 1998).
Hearts were removed from the thoracic cavity and placed in ice-cold Krebs-Henseleit
buffer (25 mM NaHCO3, 2.54 mM CaCl2, 1.18 mM MgSO4, 1.18 mM KH2PO4, 4.75
mM KCl, 118.5 mM NaCl). Upon isolation and cannulation of the aorta onto the
apparatus, hearts were initially perfused in the Langendorff mode with Krebs-Henseleit
buffer equilibrated with 95:5% O2:CO2 to flush residual blood out of the ventricles and
allow the heart to resume regular contraction. Following cannulation of the left atrium,
hearts were switched to the non-recirculating working mode and perfused for 60
minutes.
The afterload against which each heart pumped is proportional to the height of
the aortic overflow reservoir. Under steady state conditions, hearts were perfused at a
physiological workload (afterload set to 100 cm) for 60 minutes. Hearts subjected to a
high workload were perfused for 30 minutes at a physiological workload followed by 30
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minutes at an increased workload (afterload raised to 140 cm H2O, plus 1µM
epinephrine bitartrate added to the perfusate). The preload, determined by the height of
the oxygenator’s overflow above the left atrium, was set to 15 cm H2O for all perfusions.
At the end of each 60 minute perfusion, hearts were freeze-clamped while still beating
with aluminum tongs cooled in liquid nitrogen (Wollenberger and Schulze 1961).
The isolated working heart apparatus was selected as a model because it provides
numerous advantages over in vivo, in vitro, and other ex vivo approaches available. A
number of in vivo models have manipulated glucose entry into the heart by
overexpressing a transporter (Liao, Jain et al. 2002) or knocking out a receptor (Belke,
Betuing et al. 2002) necessary for glucose transport in the heart. However, in each
instance, the insult to the animal is both supraphysiological and accompanied by
compensatory changes in the heart that make it difficult to delineate the role of glucose
in cardiac growth signaling in a heart stressed in a physiological manner. In vitro
systems simply do now allow for modulating workload in the cardiomyocyte nor to
accurately measure contractile function. In other ex vivo models such as the Langendorff
preparation, the amount of perfusate pumped by the ventricles is far less than
physiological and contractile function cannot accurately assessed (Neely, Liebermeister
et al. 1967). On the other hand, there is a near-physiologic level of work performed by
the heart in the ex vivo working perfusion system (Taegtmeyer, Hems et al. 1980).
Moreover, hemodynamic stress can be applied to hearts using our system by subjecting
hearts to an ex vivo increase in workload, and both contractile function and changes in
substrate flux can be assessed in real time, as well.
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Figure 2.2 Cannulation of the left atrium and aorta. This photograph of
the perfusion apparatus highlights the placement of the isolated rat heart
within the perfusion chamber and its cannulation both at the left atrium and
the aorta. Perfusate flows in a retrograde manner from the left atrium, into
the left ventricle, and then pumped out through the aorta. The coronary
effluent is collected from perfusate that flows out the coronary arteries
proximal to where the aorta is cannulated. For orientation purposes, the
oxygenator (A), perfusion chamber (B), and compliance chamber (C) are
labeled, as well.

2.3.2.1. Perfusion Protocols and Buffers
Fresh buffer was made daily. All perfusion buffers included Krebs Henseleit
buffer (25 mM NaHCO3, 2.54 mM CaCl2, 1.18 mM MgSO4, 1.18 mM KH2PO4, 4.75
mM KCl, 118.5 mM NaCl). Buffer was prepared by adding a 20X stock solution
containing all electrolytes with the exception of CaCl2 and NaHCO3 to double distilled
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H2O and NaHCO3. The mixture was then oxygenated with 95:5% O2:CO2 for 15 minutes
before CaCl2 was added. In order to determine the effect of glucose on growth signaling
in the stressed heart, substrates were then added to the buffer to make up the perfusate,
as indicated in Table 2.2. Both metformin (Sigma Aldrich, St. Louis, MO) and 4phenylbutyrate (Calbiochem, San Diego, CA) were dissolved in H2O prior to being
added to the perfusate.
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Table 2.2 Ex vivo perfusion protocols used to study glucose activation of mTOR
signaling at high workload.*note: Four different sets of rats were perfused with
glucose and subjected to high workload. (1) The first set were untreated prior to
perfusion. (2) The second set received mTOR inhibitor rapamycin (PO, 4 mg/kg/day)
for 7 days prior to perfusion (or vehicle control). (3) The third set received metformin
(IP, 250 mg/kg/day or 500 mg/kg/day) for 7 days prior to perfusion (or vehicle
control). (4) The last set of hearts were perfused with either metformin (5 mM, 7.5
mM, or 10 mM) or 4-phenylbutyrate (PBA, 10 mM) added directly to the buffer.
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2.3.2.2. Determination of Cardiac Power, Rates of Glucose Uptake and Oxidation
Determination of Cardiac Power:
Cardiac power was used as a marker for contractile function in this project.
Cardiac power (mW) was calculated as the product of mean arterial pressure, estimated
as the height of the afterload (in cm H2O) times the cardiac output (sum of the aortic
output and coronary flow). Aortic output and coronary flows were derived by measuring
the number of seconds needed to collect 10 mL of perfusate in the aortic and coronary
overflow reservoirs, respectively, every five minutes throughout each perfusion protocol.
These measurements were then converted into mL/min by multiplying by a factor of 60.
Determination of Rates of Glucose Uptake:
Rates of glucose uptake (and subsequent phosphorylation) were determined by
adding 2-[3H]-glucose to the perfusion buffer and measuring the release of [3H]2O in the
coronary effluent. When glucose is taken up by the cardiomyocyte, it is immediately
acted upon by hexokinase and converted into glucose 6-phosphate. When glucose 6phosphate is then reversibly converted into fructose 6-phosphate by
phosphoglucoisomerase, [3H]2O is released into the coronary effluent (Katz and Dunn
1967). The overall reaction is:
2-[3H] glucose + 2 NAD+ + 2 ADP  2 pyruvate + 2 [3H]2O + 2 NADH + 2 ATP + 2H+
We collected 2 mL of coronary effluent every 5 minutes in order to assess rates of
glucose uptake throughout each 60 minute perfusion. A sample of unused perfusate was
collected at the end of each perfusion for background radioactivity measurements.
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[3H]2O was separated from unmetabolized 2-[3H] glucose and other [3H] labeled
compounds by retention and elution in an ion exchange column. Columns were packed
with glass wool and filled with 1.5 mL of AG1-X8 anion exchange resin (BioRad,
Hercules, CA). After washing the resin with 6 mL of H2O, aliquots (.5 mL) of sample
were added and eluted into scintillation vials with 3.5 mL H2O plus 13 mL Ultima Gold
liquid scintillation cocktail and radioactivity was measured by a Packard scintillation
counter, as described earlier. Specific activity, the amount of radioactivity of the
particular radionuclide (SA=tracer (dpm)/tracee (umol)), in the perfusate was
concurrently measured by adding .5 mL of unused perfusate directly to 13 mL of
scintillation cocktail.
Determination of Rates of Glucose Oxidation:
Rates of glucose oxidation were determined by adding U-[14C] glucose to the
perfusion buffer and measuring the release of [14C]O2 in the coronary effluent. [14C]O2 is
released in the Krebs Cycle when isocitrate (6C) is converted to α-ketoglutarate (5C) by
isocitrate dehydrogenase and when α-ketoglutarate (5C) is converted to succinyl CoA
(4C) by α-ketoglutarate dehydrogenase. The overall reaction is:
U-[14C] glucose  U-[14C] acetyl CoA  [14C]O2
[14C]O2 release into the coronary effluent is therefore proportional to the rate of glucose
oxidation under the given perfusion conditions and can be calculated. In each coronary
effluent sample, [14C]O2 was separated from unmetabolized U-[14C] glucose and other
[14C] labeled compounds by acidification and CO2 trapping by hyamine hydroxide
(Goodwin et al JBC 1998). Specifically, 1 mL of Hyamine Hydroxide (Perkin Elmer,
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Waltham, MA) was added to the bottom of a scintillation vial. An open eppendorf tube
containing .5 mL of coronary effluent was then placed in the scintillation vial and closed
with a subaseal rubber bung. 200 mL of 60% perchloric acid (v:v) was then injected into
each Eppendorf tube to trigger release of [14C]O2 and trapping by hyamine hydroxide.
Each scintillation vial was stored overnight to allow the reaction to occur to completion.
13 mL Ultima Gold liquid scintillation cocktail was added the next morning and
radioactivity was measured by a Packard scintillation counter, as described earlier.

2.3.3. Spectrophotometric enzymatic metabolite analysis
Using heart tissue that had been stored at -80oC, approximately 500 mg of
pulverized frozen heart tissue was added to .5 mL 6% perchloric acid on ice to
precipitate out proteins and halt all metabolic activity (Wiliamson, Corkey 1967). Tissue
was then homogenized for roughly 30 seconds with a Polytron® homogenizer. The
suspension was then neutralized by the addition of KIK (6M KOH, .4M imidazole, .4M
KCl), vortexed, and centrifuged at 13,000 rpm to isolate out metabolites. Metabolite
concentrations were then determined by enzymatic spectrophotometric analysis, as
detailed below. In each instance, absorbance at 340 nm was read in samples placed in
plastic cuvettes (10 mm light path) before and after addition of enzyme. Incremental
changes in absorbance with time indicated when each reaction was completed.
Metabolite concentrations of glucose 6-phosphate, fructose 6-phosphate, and
adenosine-5’-triphosphate (ATP) were measured by a spectrophotometric enzymatic
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analysis using glucose-6-phosphate dehydrogenase coupled to NADPH production with
extinction at 340 nm.
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Similarly, conentrations of adenosine-5’-diphosphate (ADP) and adenosine-5’triphosphate (ATP) were measured using lactate dehydrogenase coupled to the oxidation
of NADH to NAD+ with extinction at 340 nm (Bergmeyer 3rd edition) in a three-step
reaction.

A colorimetric Bradford assay was completed to determine the total protein
concentration in each sample (Bradford 1976). Metabolite concentrations were
normalized to total protein content in each sample.
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2.3.4. Western Immunoblotting
Protein Extraction
Total protein was extracted from frozen heart tissue by homogenizing 100 mg
left ventricular tissue at maximum speed for 30 seconds in extraction buffer (30 mM
Hepes, 2.5 mM EGTA, 2.5 mM EDTA, 20 mM Kcl, 40 mM glycerophosphate, 40 mM
NaF, 4 mM NaPPi 10% glycerol, .1% non-idet P40) using a Polytron® homogenizer.
The suspension was then centrifuged for 30 minutes at 13,000 rpm and the supernatant
(protein) was recovered. A colorimetric Bradford assay was completed to determine the
protein concentration in each sample (Bradford Anal Biochem. 1976). Aliquots of 25 ug
were prepared in 2X protein loading buffer (1M Tris HCl, glycerol, 10% SDS, .1%
Bromophenol Blue, 2-mercaptoethanol) and stored at -80oC.

Western blotting
Protein lysates were separated by SDS-PAGE (polyacrylamide gel
electrophoresis) and transferred onto a nitrocellulose membrane using a Trans-Blot SD
Semi-Dry Electrophoretic Transfer Cell (BioRad, Hercules, CA). Ponceau staining of the
membrane was used to confirm uniform transfer of proteins throughout the membrane.
Membranes were destained with .4% TBS-T (Tris base in NaCl, in .4% tween-20
detergent) then washed in 5% nonfat milk in TBS-T for two hours at room temperature
to block non-specific sites on the membrane. Membranes were then incubated at 4oC in
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primary antibody solution (in 5% BSA in TBS-T) overnight. After unbound primary
antibody was washed off with TBS-T the next morning and the membrane was incubated
in horseradish peroxidase (HRP)-conjugated secondary antibody for one hour at room
temperature. Subsequent addition of a chemiluminescent luminol reagent produced light
that was captured on film and developed in a dark room. Changes in the phosphorylated
protein to total protein ratio by Western immunoblotting is uniformly accepted as an
indicator of protein activation/inactivation along the mTOR signaling cascade and was
therefore assessed in all hearts.

2.3.5. Quantitative Reverse Transcription Polymerase Chain Reaction (qRTPCR)
RNA Extraction
Total RNA was extracted from frozen heart tissue by first homogenizing 100 mg
left ventricular tissue at maximum speed for 30 seconds in guanidinium thiocyanatephenol-chloroform extraction (Tri-Reagent, MRC, Cincinnati, OH). The suspension then
underwent phase separation by a series of centrifugation steps. In the final step, RNA
was precipitated out of the aqueous phase by isopropanol. RNA concentration was then
measured with a Nanodrop ND-1000 Spectrophotometer. All RNA samples were diluted
to a final concentration of 30 ng/uL and stored at -80oC. 60 ng of RNA were analyzed in
triplicate per sample.
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qRTPCR
RNA was first reverse transcribed into its complementary DNA by reverse
transcriptase (Invitrogen, Carlsbad, CA) and the resulting cDNA was amplified by realtime PCR using the ABI Prism 7100 SDS. On each 96-well plate, select samples were
also run in the absence of reverse transcriptase to detect DNA contamination. These
samples served as the non-amplified control (NAC). Fluorescence is produced by
cleavage of a reporter dye from a quencher dye on a nucleic acid probe that is degraded
by Taq polymerase during each cycle of PCR. The number of cycles necessary to reach a
fluorescence threshold (Ct) is used to determine the amount of RNA transcripts present
in each sample compared to standard amounts of RNA over a log range of
concentrations (Fig. 2.3). Data are presented as transcript copy per nanogram of RNA.
Primer and probe sequences have been previously published (Harmancey, Wilson et al.
2010) and are listed below:

Glucose Regulated Protein 78 (GRP78)
Forward 5‟-ACCGTCGTATGTGGCCTTCA-3‟
Reverse 5‟-TCCGGGTTGGACGTGAGTT-3‟
Probe 5‟-FAM-CTGATTGGCGATGCGGCC-TAMRA-3‟
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Glucose Regulated Protein 94 (GRP94)
Forward 5‟-TGTCAAAGGTGTTGTGGATTCC-3‟
Reverse 5‟-AGAGTTTTGCGGACAAGCTTCT-3‟
Probe 5‟-FAM-TCTCCCCCTCAATGTTTCCCGTGA-TAMRA-3‟

Endoplasmic Reticulum Protein 72 (ERp72)
Forward 5‟-CTTCTAACGATGCTAAGCGGTACA-3‟
Reverse 5‟-CGCCAAAACTGAGTAGCAGTTCT-3‟
Probe 5‟-FAM-CAAGCGCCCCCTGGTGGTTGTA-TAMRA-3‟
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Figure 2.3 Sample Standard Curve Used to Quantify mRNA Transcript levels of
ER stress markers. The fluorescent signal for up to 40 cycles of PCR are recorded
from standard amounts of mRNA. A non-amplification control (NAC, sample without
reverse transcriptase) is run alongside each set of samples.
2.3.6 Statistical Analysis
Two way repeated measures analysis of variance (ANOVA) and Holm-Sidak
post hoc test were used to compare cardiac power, rates of glucose uptake, and rates of
glucose oxidation between different groups of hearts perfused ex vivo. All numerical
data were displayed as a mean ± SEM. A p<0.05 was considered statistically significant.
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CHAPTER 3: LOAD-INDUCED MTOR ACTIVATION IS MEDIATED BY
GLUCOSE 6-PHOSPHATE ACCUMULATION
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3.1 Introduction

This chapter includes rationale, results, and discussion of the experiments in
support of the hypothesis that load-induced mTOR activation is mediated by glucose 6phosphate accumulation. Hypertension, valvular heart disease, anemia, and prior
myocardial infarctions all stress the heart with an increase in workload and can
ultimately lead to heart failure. Metabolically, hearts increase their reliance on glucose
for energy provision (Goodwin, Taylor et al. 1998) and structurally, hearts hypertrophy
when stressed (Dorn and Force 2005). However, the mechanisms that trigger a heart to
hypertrophy and ultimately fail under such conditions remain largely unknown. We
therefore investigated whether the metabolic remodeling process drives the structural
and functional remodeling process in hearts subjected to high workload via mTOR
activation.
Load-induced cardiac hypertrophy is largely driven by the mammalian target of
rapamycin (mTOR), a major regulator of protein synthesis that is located dowstream of
the PI3K-Akt signaling pathway (Fig. 3.1). mTORC1 directly triggers cardiac
hypertrophy via activation of p70S6 kinase (p70S6k) and 4E-binding protein 1 (4EBP1),
which promote ribosomal biogenesis and CAP-dependent protein translation,
respectively.
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Figure 3.1 Proposed activation of the mTOR signaling pathway by glucose. Loadinduced mTOR activation is known to occur via the PI3K-Akt signaling pathway.
Whether the heart’s increased reliance upon glucose at high workload regulates this
signaling pathway is unknown.
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mTORC1 plays a critical role in promoting cardiac growth in response to
increased workload (Shioi, McMullen et al. 2003). mTOR also couples energy and
nutrient abundance to cell growth owing ot the capacity to sense nutrients, stress, and
growth factors (Zoncu, Efeyan et al. 2011). It is also known to be activated by nutrients
and growth factors (Proud 2002). Whether load-induced mTORC1 activation in the heart
is regulated by physiological changes in energy substrate metabolism in the stressed
heart was unknown at the beginning of my project. We previously reported that the
insulin signaling pathway and mTORC1 can only be activated by the combination of
glucose and insulin in rat heart (Sharma, Guthrie et al. 2007). I extended this work and
investigated the metabolic, functional and structural consequences of glucose-mediated
mTOR signaling in the stressed heart.
The chapter addresses the following four objectives: 1) Determining whether in
hearts subjected to increased workload in vivo, metabolic remodeling precedes the
structural and functional remodeling process. 2) Determining whether load-induced
mTOR activation is dependent upon the heart’s increased reliance upon glucose at high
workload. 3) Elucidating the mechanism by which changes in glucose metabolism
modulate phosphorylation (i.e. activation) of proteins along the PI3K/Akt and
TSC2/mTOR axis at high workload. 4) Identifying the functional consequences of
sustained mTOR activation and determining whether these consequences are
preventable.
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We investigated whether signals generated by glucose metabolism regulate
mTOR activation in the heart when it is subjected to high workload. I tested this
hypothesis by first subjecting mice to increased workload in vivo and serially monitoring
changes in glucose metabolism, contractile function, and structure using PET and MRI
imaging. I then assessed mTOR activation in these hearts to determine whether the
metabolic or structural changes were associated with changes in mTOR activation. Next,
to determine the mechanism by which changes in glucose metabolism regulate mTOR
activation in vivo, I systematically modulated substrate supply and workload to the heart
ex vivo and assessed changes in the activation of nearly every major protein involved in
the mTOR signaling cascade. Lastly, I investigated whether or not markers of loadinduced mTOR activation were metabolically regulated in left ventricular tissue from
failing human hearts before and after implantation of an LVAD. My objective was to
establish that pathways of protein synthesis are metabolially regulated in the heart and to
determine whether any of the findings in animal models are also present in th failing
human heart. It was my expectation that these results provide evidence to support the
idea that modulation of cardiac metabolism can be used to regulate cardiac growth and
contractile function.
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3.2 Results

3.2.1. Metabolic Remodeling Accompanies Functional but Precedes Structural
Remodeling In Response to Increased Workload In Vivo

In order to determine whether enhanced glucose uptake precedes the structural
and functional remodeling process in response to increased cardiac workload in vivo,
mice were serially imaged with FDG-PET and MRI 1 day, 2 weeks, and 4 weeks to
transverse aortic constriction (TAC) in the laboratory of our collaborator Bijoy Kundu at
the University of Virginia. Transverse end-diastolic FDG-PET images demonstrated a 5fold increase in the rate of myocardial FDG uptake beginning 1 day after TAC, which
further increased (1.5- to 3.2-fold) over 4 weeks (Fig. 3.2A-B). Sham operated animals
showed no change in FDG uptake over the same period. The PET images also suggested
hypertrophy and an enlargement in LV cavity in the TAC mice, but only at 2 and 4
weeks.
While metabolic remodeling was detected 1 day after TAC, no structural changes
were appreciated at this early time point by MRI. There was no significant increase in
either the heart weight to body weight ratio (HW/BW) (Fig. 3.2C) or end diastolic wall
thickness (Fig. 3.2D) 1 day after TAC. Both HW/BW and end diastolic wall thickness
exhibited a 1.4 fold increase only after 2 and 4 weeks after TAC. There was no
significant change in HW/BW or wall thickness over 4 weeks in sham-operated mice.

61

Figure 3.2 Metabolic remodeling precedes structural remodeling in hearts
subjected to high workload in vivo. (A) 1 day after TAC, there is an increase in
FDG uptake prior to any structural changes in the heart. (B) Myocardial FDG uptake
(Ki) in TAC mice demonstrates a 5-fold increase in FDG uptake at day 1, and a 1.5to 3.2-fold increase from day 1 to 4 weeks. Sham operated mice show no significant
change in FDG uptake over 4 weeks. (C) Body weight (BW) was recorded and heart
weight (HW) was measured using MRI in vivo. HW/BW remains unchanged 1 day
after TAC, but increases 1.4- and 1.7-fold between day 1 and 4 weeks, respectively.
HW/BW shows no significant change over 4 weeks in sham operated mice. (D) End
diastolic wall thickness is unchanged 1 day after TAC, but increases about 1.4-fold
between day 1 and 4 weeks. Wall thickness shows no significant change over 4
weeks in sham operated mice. n=8 for the TAC and n=5 for the shams. All values are
mean ± SD. #p<0.05 day 1 vs BSL, *p<0.001 vs BSL, day 1, 2 weeks, **p<0.05 vs
BSL, day 1; ^p<0.05 between the TAC and sham groups on the same day. Imaging
studies and analysis were completed at our collaborator Bijoy Kundu’s laboratory at
The University of Virginia Medical School.

In order to determine whether functional changes accompanied the early
metabolic or later structural changes in response to high workload, end-diastolic volume
(EDV), end-systolic volume (ESV) and ejection fraction (EF) were also assessed by
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MRI. There were no significant changes in EDV at 1 day after TAC (Fig. 3.3A), but
there were increases in ESV (Fig. 3.3B) and significant decreases in EF (Fig. 3.3C) at
the same time point. Both ESV and EDV (Fig. 3.3A-B) progressively increased 2 and 4
weeks after TAC, while the EF progressively declined over the same time period. There
were no significant changes in EDV, ESV, or EF in sham operated animals over 4
weeks. Collectively, the data support the hypothesis that metabolic changes precede
structural changes and accompany functional changes in hearts subjected to increased
workload in vivo.
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Figure 3.3 Functional changes accompany metabolic changes in response to high
workload. (A) End-systolic volume (ESV), (B) end-diastolic volume (EDV), and
resultant (C) ejection fractions (EF) were assessed in vivo using MRI. An increase in
ESV and decline in EF is present 1 day after TAC. Sham operated mice exhibited no
significant change in EDV, ESV and EF over 4 weeks. n=8 for TAC group and n=5
for the shams. All data are mean ± SD. In the plot for ESV, *p<0.005 vs BSL and 1d;
**p<0.05 vs BSL and 1d. In the plot for EDV, *p<0.01 vs BSL and 1d. In the EF
plot, *p<0.05 vs 1 d, 2 wks and 4 weeks; ^p<0.05 between the TAC and sham groups
on the same day. Data are from Dr. Kundu’s lab at The University of Virginia.

3.2.2. My central hypothesis: Load-Induced mTOR Activation Requires Glucose

Because metabolic changes occur instantaneously in response to increased
workload in vivo (as seen above already 1 day after TAC), it was difficult to distinguish
whether the ‘load-induced’ changes in contractile function and mTOR activation were in
fact metabolically regulated or not. At this point, it remained a distinct possibility that
the heart’s observed increased reliance upon glucose in vivo occurred simultaneously,
but independently, to the changes in cardiac growth. In order to determine whether loadinduced mTOR activation and contractile dysfunction is regulated by glucose
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metabolism, cardiac substrate supply and workload were independently modulated ex
vivo. I performed four sets of matched perfusions: (1) at normal workload (nearphysiologic) with acetoacetate plus propionate (control with only non-carbohydrate
substrates, NCS) (2) at increased workload (high physiologic) with NCS (control) (3) at
normal workload with glucose (at physiologic 5 mM concentration) as the only substrate
(4) at increased workload with glucose (5 mM) as the only substrate. A second set of rats
were pretreated with mTOR inhibitor rapamycin (PO, 4 mg/kg/day) or vehicle control
(propylene glycol) 7 days prior to sacrifice. The hearts were subjected to the same
protocols to assess whether changes in cardiac power were in fact due to changes in
mTOR activation or not. Cardiac power was assessed and the hearts were freezeclamped at the end of the perfusion protocol at 60 minutes.
We determined that increased workload (depicted as orange) triggers
phosphorylation of upstream PI3K and Akt in all rat hearts irrespective of substrate
supply. However, increased workload alone is not sufficient to activate TSC2, mTOR, or
its downstream targets. Maximal TSC2, mTOR, p70S6K, and 4EBP1 phosphorylation
occurs only in hearts perfused with glucose and subjected to increased workload (Figure
3.4).
Others in the lab had previously demonstrated that 7 day rapamycin pretreatment
prior to perfusion effectively inhibits mTOR in the isolated working rat heart (Sharma,
Guthrie et al. 2007). I now elucidated its effect on the entire mTOR signaling pathway.
Rapamcyin pretreatment did not effect PI3K phosphorylation, but inhibited
phosphorylation of Akt, TSC2, mTOR, p70S6K, and 4EBP1 in hearts subjected to
increased workload with glucose. Not surprisingly, the mTOR signaling cascade was not
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activated in hearts perfused at normal, physiological workload in the presence or absence
of glucose (blue).

Figure 3.4 In hearts subjected to high workload, glucose activates mTOR.
The mTOR signaling pathway was assessed by western blot in isolated
working rat hearts perfused as described in Table 2.2. Increased
phosphorylation of upstream PI3K and AKT were seen in all hearts perfused
at high workload. Increased phosphorylation of TSC2, mTOR and p70S6K
required glucose at high workload. Rapamycin administration for 7 days (4
mg/kg/day) prior to perfusion inhibited phosphorylation of Akt, TSC2,
mTOR, and its downstream targets. The perfusion medium contained no
insulin. NCS refers to noncarbohydrate substrates (acetoacetate, 7.5 mM and
propionate, 5 mM); Glucose refers to hearts perfused with only glucose (5
mM).
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Next I wanted to demonstrate that hearts perfused ex vivo with physiological
concentrations of glucose, fatty acids, acetoacetate, and propionate (mixed) would
demonstrate these same properties, we also assessed the phosphorylation of P70S6K and
4EBP1 in hearts perfused with mixed substrates at normal and high workload. Like
hearts perfused with glucose alone, hearts perfused with mixed substrates demonstrated
increased phosphorylation of P70S6K and 4EBP1 at high workload (Fig 3.5). This
suggested that amongst the substrates that perfuse the heart, glucose alone is sufficient
for mTOR activation at high workload.

Figure 3.5 In the presence of mixed substrates, mTOR signaling is activated and
G6P levels are elevated at high workload. P70S6K and 4EBP1 phosphorylation were
increased to the same extent in hearts perfused at high workload with mixed substrates
compared to hearts perfused with glucose alone. Data are shown as mean ± SEM, n=5-8.
See text and earlier figures for definition of terms. Mixed refers to hearts perfused with a
mixture of substrates at physiologic concentrations (glucose at 5 mM, oleate at .4 mM,
acetoacetate at 7.5 mM, and propionate at 5 mM).
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3.2.3. mTOR Activation Impairs Contractile Function At High Workload

To determine the functional consequence of glucose-mediated mTOR activation,
we calculated cardiac power in all perfused hearts (Figure 3.6). Under all conditions,
cardiac power was stable both at normal workload and at increased workload,
representing the stability of the model. At normal workload, there was no significant
difference in cardiac power between hearts perfused with glucose (11.89± 1.3 mW) and
hearts perfused with NCS (12.12± 0.83 mW). However, when subjected to increased
workload ex vivo, hearts perfused with glucose (16.37± 1.5 mW) displayed in a 29%
decrease in cardiac power compared to hearts perfused with NCS (18.91± 0.84 mW).
Rapamycin pretreatment for 7 days prior to perfusion prevented the decline in contractile
function in hearts perfused with glucose at increased workload (20.75± 1.32 mW),
suggesting that the decreased cardiac output in hearts perfused with glucose at high
workload is mTOR-dependent. The mechanism for this phenomenon is unknown but
may relate to the unfolded protein response (see next chapter). Rapamycin had no
significant effect on cardiac power in hearts perfused with NCS or in hearts perfused at
normal (near-physiological) workload (not shown for clarity).
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Figure 3.6 In hearts subjected to high workload, cardiac power is impaired
when glucose is the only substrate. Rapamycin rescues contractile function.
Cardiac power was assessed every 5 minutes throughout each 60 minute
perfusion. At normal workload, neither glucose nor rapamycin had an effect on
cardiac power. At increased workload, glucose impaired cardiac power.
Rapamycin improved contractile function in stressed hearts perfused with
glucose. Rapamycin did not change contractile function in hearts perfused with
NCS (data not shown for clarity). Data are shown as mean ± SEM, n=5-8,
*p<0.002 compared to hearts perfused with NCS + vehicle and glucose +
rapamycin at high workload.
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3.2.4

High Workload Induces A Mismatch Between Rates Of Glucose Uptake

And Oxidation

To elucidate the mechanism of glucose-mediated mTOR activation, I assessed
rates of glucose uptake and oxidation under all conditions. In vehicle treated rats, rates
of glucose uptake (4.2 ± 0.7 µmoles/min/g dry wt) matched rates of glucose oxidation
(3.9 ± 0.7 µmoles/min/g dry wt) at normal workload. When subjected to increased
workload, rates of glucose uptake (11.5± 0.8 µmoles/min/g dry wt) exceeded rates of
glucose oxidation (9.5± 0.6 µmoles/min/g dry wt). Pretreatment with the mTOR
inhibitor rapamcyin (4 mg/kg/d) for 7 days prevented this mismatch between glucose
uptake and oxidation. Pretreatment of rats with rapamycin reduced rates of glucose
uptake (4.4± 0.7 µmoles/min/g dry wt) and glucose oxidation (4.3± 0.7 µmoles/min/g
dry wt) when hearts were subjected to increased workload (Fig. 3.7). This observation
suggests the following – there is an increase in cardiac efficiency when animals are pretreated with rapamycin, and the metabolic stress of glucose in the hearts from untreated
animals leads to proteotoxicity (discussed below).
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Figure 3.7 Rates of glucose uptake exceed rates of glucose oxidation in
response to high workload. Rapamycin corrects this mismatch. Rates of
glucose uptake and oxidation were closely coupled at normal workload (in both
vehicle and rapamycin treated rats). At high workload, rates of glucose uptake
exceeded rates of glucose oxidation in vehicle treated rats. Rapamycin treatment
significantly reduced rates of both glucose uptake and oxidation. * p<0.05 versus
rates of glucose uptake in vehicle treated rats. #p<.001 versus metabolic rates in
vehicle treated rats.
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3.2.5. Glucose 6-Phosphate Accumulates At High Workload as a Consequence of a
Mismatch between Rates of Glucose Uptake and Oxidation

Because mTOR activation was associated with a mismatch between glucose
uptake and oxidation, we investigated whether the accumulation of glucose or one of its
metabolites correlated with mTOR activation. Levels of glucose 6-phosphate (G6P)
directly correlated with mTOR activation (Fig. 3.7-3.8). G6P levels were 4.3-fold higher
in hearts subjected to an acute increase in workload (4.4± 1.0 nmoles/mg protein)
compared to hearts perfused at physiologic workload (1.0± 0.5 nmoles/mg protein).
Rapamycin pretreatment blunted G6P levels (0.36± 0.1 nmoles/mg protein) in hearts
perfused at increased workload. In contrast, levels of other upstream glycolytic
intermediates were unchanged at high workload.
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Figure 3.8 G6P accumulates in response to high workload. Cardiac G6P levels
were assessed in freeze-clamped hearts. Subjecting hearts to high workload ex
vivo induced a 4-fold increase in G6P levels, which was reversed with rapamycin
treatment. Rapamycin = hearts from animals pretreated with rapamycin for 7
days. See text for further detail.
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3.2.6. Accumulation Of Glucose 6-Phosphate Analogue 2-Deoxy-Glucose 6Phosphate Activates mTOR

To verify whether G6P accumulation was a cause or consequence of mTOR
activation in hearts subjected to increased workload, I perfused hearts with the following
glucose analogues: (1) 3-O-methylglucose (which is taken up by the cardiomyocyte but
not metabolized) and (2) 2-deoxyglucose (which is taken up by the cardiomyocyte,
phosphorylated and trapped as a G6P analogue) (Fig. 3.9). Following perfusion, Akt,
TSC2, mTOR and p70S6K phosphorylation were assessed in freeze-clamped hearts. At
high workload, increased AKT phosphorylation was present when hearts were perfused
with both 3-O-methylglucose and 2 DG. However, 3-O-methylglucose was unable to
increase phosphorylation of TSC2, mTOR or its downstream target p70S6K in hearts
perfused at high workload. However, 2-deoxyglucose phosphorylated TSC2, mTOR and
p70s6k to an even greater extent then in hearts perfused with glucose at high workload.
mTOR and p70S6K were not phosphorylated in hearts perfused with either glucose
analogue at normal workload. Hexose 6-phosphate levels were assessed by enzymatic
spectrophotometric analysis and demonstrated that a correlation with mTOR activation
in hearts perfused with non-metabolizable glucose analogues, as well (Fig. 3.10). These
experiments provide further evidence that G6P is associated with mTORC1 activation in
hearts subjected to increased workload.
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Figure 3.9 Glucose analogues used in isolated working heart perfusions. Hearts were
perfused ex vivo for either 60 minutes under normal workload (pink) or for 30 minutes
under normal workload and subsequently for 30 minutes at high workload (red). Hearts
were perfused with either glucose, 2-deoxyglucose (which is phosphorylated by
hexokinase and retained in the cardiomyocyte as the G6P analogue, 2-DG 6-P), or 3-Omethylglucose (which cannot be acted upon by hexokinase and remains in the
cardiomyocyte as a free glucose analogue). All hearts perfused with glucose analogues
were also perfused with acetoacetate (7.5 mM) and propionate (5 mM) for energy
provision.

Figure 3.10 Increased phosphorylation of mTOR and p70S6K is associated with
increased hexose 6-phosphate levels in hearts perfused with 2DG. Representative western
blots of Akt, TSC2, mTOR and p70S6K phosphorylation in hearts perfused with glucose and
glucose analogues 2 deoxyglucose (2DG) and 3-O-methylglucose (3OMG) at either normal
or high workload. 2DG, but not 3OMG, increased phosphorylation of TSC2, mTOR, and
p70S6K at high workload. Hearts perfused with 2DG had significantly increased levels of
intracardiac hexose 6-phosphate levels. All hearts perfused with glucose analogues were also
perfused with acetoacetate (7.5 mM) and propionate (5 mM) for energy provision.
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3.2.7. Glucose 6-Phosphate-dependent mTOR Activation is Mediated By
Downregulation of AMPK

Up to this point my data suggest that TSC2 or one of its upstream regulators
mediates G6P-dependent mTOR activation in the heart. AMPK is a heterotrimeric
enzyme that lies upstream of TSC2 and regulates fuel supply and substrate metabolism
in response to the metabolic milieu of the heart. When phosphorylated at Thr 172,
AMPK phosphorylates acetyl co-A carboxylase (ACC) at Ser 79, a commonly used
marker of AMPK activation, and phosphorylates TSC2 at Ser1387 and RAPTOR at Ser
792 to inhibit mTOR (Young, Cell Metabolism 2008). High glucose-mediated mTOR
activation is regulated by a downregulation in AMPK in skeletal muscle (Saha et al.
Diabetes 2010). I therefore examined changes in AMPK phosphorylation in all perfused
hearts. Neither increased workload nor glucose alone was associated with a change in
AMPK phosphorylation. However, perfusion at increased workload with glucose led to a
downregulation of phospho-AMPK (Thr 172), phospho-ACC (Ser 79) and phosphoTSC2 (Ser 1387). Rapamycin treatment prevented the downregulation of AMPK, ACC,
and TSC2 phosphorylation. RAPTOR phosphorylation was unchanged with workload or
rapamycin treatment (Fig. 3.11).
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Figure 3.11 G6P-dependent mTOR activation is mediated by AMPK
downregulation. (A) Representative western blots demonstrate a reduction in AMPK
phosphorylation (T 172) and ACC phosphorylation (Ser 79) in hearts perfused with
glucose at high workload.
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3.2.8 Metformin Inhibits mTOR Activation and Rescues Contractile Function at
High Workload
To confirm whether AMPK downregulation was necessary for glucosedependent mTOR activation and to determine whether it could be prevented with
metformin (AMPK activator) pretreatment, rats were systemically pre-treated with either
control (NaCl) or metformin in vivo for 7 days (IP, 250 mg/kg/d or 500 mg/kg/d) prior to
being perfused with glucose at high workload. Compared to control treatment,
metformin prevented AMPK downregulation and inhibited mTOR, p70S6K, and 4EBP1
phosphorylation in a dose-dependent manner (Fig. 3.12). In order to determine whether
these effects were due to metformin’s systemic effects or direct effects in the heart, I
perfused hearts with glucose at high workload in buffer that contained metformin at
three doses (5 mM, 7.5 mM, 10 mM). Ex vivo perfusion with metformin also prevented
AMPK downregulation and inhibited mTOR, p70S6K, and 4EBP1 phosphorylation in a
dose-dependent manner in hearts perfused at high workload with glucose (Fig. 3.12).
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Figure 3.12 G6P-dependent mTOR activation is inhibited by metformin. Both in
vivo metformin prior to perfusion and ex vivo metformin during perfusion increased
AMPK phoshphorylation and prevented P70S6K phosphorylation in a dosedependent manner.
We assessed rates of glucose uptake and oxidation as well as cardiac glucose 6phosphate levels in these hearts, as well. In unstressed hearts (perfused at normal
physiologic workload), systemic in vivo metformin treatment did not significantly
change rates of glucose uptake or glucose oxidation. In hearts subjected to high
workload, in vivo metformin treatment did not change rates of glucose uptake (11.7± 1.1
µmoles/min/g dry) but increased rates of glucose oxidation (11.0± 0.7 µmoles/min/g
dry) and blunted G6P accumulation compared to vehicle treated animals (Fig 3.13).
Metformin improved cardiac power 26% in hearts perfused at increased workload with
glucose (Fig. 3.14). Metformin treatment had no effect on mTOR phosphorylation or
cardiac power in hearts perfused at physiologic workload.
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The major regulator of AMPK is a shift in the AMP:ATP ratio. Therefore, I also
assessed AMP, ADP, and AMP levels in all perfused hearts. Surprisingly, I found no
significant change in their levels under any perfusion condition (Table 3.1).

Figure 3.13 Metformin treatment corrects the mismatch between rates of
glucose uptake and oxidation at high workload and blunuts G6P accumulation.
Rates of glucose uptake and oxidation were closely coupled at normal workload (in
both vehicle and metformin treated rats). At high workload (stressed), metformin
corrected the mismatch between rates of glucose uptake and oxidation (top). G6P
accumulation was reduced in hearts perfused at high workload with glucose after
metformin treatment (bottom). * p<0.05 versus rates of glucose uptake in vehicle
treated rats. #p<.001 versus metabolic rates in vehicle treated rats.
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Figure 3.14 Metformin treatment improves cardiac power at high workload.
Contractile performance in the isolated working rat heart perfused with glucose in the
presence and absence of metformin treatment. n=5-8; *p<0.05
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3.2.9

Glucose Phosphorylation Modulates mTOR Activation in vivo (TAC and

ACSL-/- mice)

To determine whether changes in glucose metabolism led to G6P accumulation
in mouse hearts subjected to increased workload in vivo, I assessed cardiac G6P
accumulation and mTOR activation in mice that were sacrificed one day and two weeks
after transverse aortic constriction (TAC). We selected hearts at one day (before
significant structural and functional changes) and two weeks (after significant structural
and functional changes) after TAC in order to check the validity of our hypothesis that
metabolic changes precede, trigger, and sustain structural and functional changes in
hearts subjected to increased workload in vivo. Cardiac G6P levels are 2.3-fold and 4.6fold higher compared to sham-operated animals 1 day and 2 weeks after TAC,
respectively (Fig. 3.15). Both P70S6K and 4EBP1 phosphorylation were significantly
increased both 1 day and 2 weeks after TAC compared to sham-operated mice (Fig
3.16).
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Figure 3.15 Early metabolic changes are associated with G6P accumulation in hearts
subjected to high workload in vivo. Intracardiac G6P levels are 2.3-fold and 4.6-fold
higher compared to sham-operated animals 1 day and 2 weeks after TAC, respectively.
n=5-8; *p<0.05

Figure 3.16 Early metabolic changes are associated with mTOR activation in hearts
subjected to high workload in vivo. Representative western blots demonstrate an increase
in p70S6K and 4EBP1 phosphorylation 1 day and 2 weeks after TAC. n=8 for the TAC and
n=5 for the sham operated mice. *p<.002
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Next, I tested my hypothesis in a genetic model that was metabolically similar to
the pressure overload-induced hypertrophied heart by using the cardiac specific longchain acyl coenzyme A synthetase (ACSL) -/- mouse. ACSL is necessary to activate
fatty acids to their acyl coenzyme A counterparts before they can be oxidized.
Accordingly, mice hearts lacking ACSL have marked reductions in fatty acid oxidation
and rely primarily on carbohydrate metabolism for energy provision (Ellis, Mentock et
al. 2011). As already observed in the ex vivo hearts subjected to increased workload,
hearts from ACSL -/- mice demonstrate a downregulation of AMPK and an activation of
mTOR in the absence of any increased mechanical load placed on the heart (Ellis,
Mentock et al. 2011). Moreover, the changes in AMPK signaling are independent of any
change in the AMP/ATP ratio, as well. We assessed G6P accumulation in these mouse
hearts and demonstrated that G6P accumulation was associated with mTOR activation in
this mouse model, as well (Fig 3.17).

Figure 3.17 G6P accumulation correlates with mTOR activation in the ACSL -/mouse. Intracardiac G6P levels are 2.5-fold higher in ACSL -/- mice compared to WT
mice. N=5. Data are presented as mean ± SEM.
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3.2.10 Mechanically unloading failing human hearts with a left ventricular assist
device (LVAD) reduces Glucose 6-Phosphate levels and mTOR Activation

When the human heart is subjected to sustained increases in workload it
ultimately fails. Changes in substrate energy have been observed in failing human hearts
metabolism (Razeghi, Young et al. 2001; Kato, Niizuma et al. 2010), but the effect of
mechanical unloading on intermediary glucose metabolism and mTOR signaling is not
known. In order to gain insight into whether ‘load-induced’ cardiac growth is governed
by G6P accumulation in the failing human heart, I obtained cardiac tissue from Dr. O.H.
Frazier and his team at the Texas Heart Institute during LVAD implantation and again
during explantation from 11 non-diabetic patients with idiopathic dilated
cardiomyopathy and assessed the tissue for changes in G6P concentration and mTOR
activation. G6P levels significantly decreased after mechanical unloading (Fig. 3.18A-B)
as did phosphorylation of p70S6K and 4EBP1 (Fig. 3.18C).
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Figure 3.18 Mechanical Unloading of Failing Human Hearts Reduces G6P
accumulation and mTOR activation. (A) Intracardiac G6P levels in each patient with
idiopathic dilated cardiomyopathy before after mechanical unloading. (B) Average G6P
levels demonstrate a dramatic reduction at time of explant from LVAD. (C)
Representative western blots demonstrate a reduction in mTOR downstream targets
P70S6K and 4EBP1 in failing human hearts after mechanical unloading. n=11 paired
samples. Panel A traces individual patients. Panel B shows mean ± SEM* p< 0.05
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3.3 Discussion

Hemodynamic stress induces instant quantitative and qualitative changes in the
use of energy providing substrates (Goodwin, Taylor et al. 1998). The structural and
functional response to increased workload has been extensively studied in the murine
transverse aortic constriction (TAC) model (Rockman, Ross et al. 1991). How the
metabolic response to increased workload regulates these changes has previously not
been investigated.
I interrogated the consequences of these early metabolic changes and
demonstrated that signals generated by glucose metabolism are associated with mTOR
activation and impaired contractile function. The main findings are: 1) In hearts
subjected to increased workload in vivo, metabolic remodeling precedes structural
remodeling of the heart and accompanies load-induced mTOR activation and contractile
dysfunction. 2) Doubling the workload ex vivo increases rates of myocardial glucose
uptake beyond the heart’s oxidative capacity, resulting in G6P accumulation, which
mediates load-induced mTOR activation. 4) Correcting the mismatch between glucose
uptake and oxidation in the stressed heart with mTOR inhibitor rapamcyin or AMPK
activator metformin prevents G6P accumulation and rescues contractile function in
hearts subjected to increased workload. 5) In the failing human heart, mechanical
unloading decreases levels of G6P as well as phosphorylation of p70S6K and 4EBP1.
This makes it likely that G6P induced changes in mTOR activation and ER stress are of
clinical relevance for the failing human heart.
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While the normal heart primarily oxidizes fatty acids (Bing, Siegel et al. 1954),
increased energy requirements of hearts subjected to high workload are met by the
oxidation of carbohydrates (Goodwin, Taylor et al. 1998). The classic explanation for
this phenomenon is based on the fact that the heart oxidizes the most efficient substrate
for a given situation (Taegtmeyer, Hems et al. 1980). Specifically, it can be reasoned
that at a high workload the heart would prefer to utilize glucose since it generates more
moles of ATP per O2 consumed compared to fatty acids (Korvald, Elvenes et al. 2000).
I asked myself the question: what if changes in substrate utilization regulate more than
just energy provision?
It is already known that aside from merely providing energy for cell function,
glucose metabolites regulate gene expression in the liver and pancreatic β-cell (Girard,
Ferre et al. 1997; Schuit, Huypens et al. 2001) and that long-chain fatty acids are ligand
activators of PPARα in the heart (Finck and Kelly 2007). The lab initially had asked the
question: could glucose-driven metabolic gene expression also occur in the heart?
Previous work demonstrated that changes in glucose metabolism are linked to
transcriptional changes in gene expression in the heart (Young, Yan et al. 2007). More
specifically, we recently suggested that the metabolite G6P mediates activation of
transcription factor carbohydrate responsive binding protein (Li, Chen et al. 2010). This
work was conducted in parallel with our studies showing that glucose metabolism is
required for insulin-dependent mTOR activation in the heart (Sharma, Guthrie et al.
2007). I now provide new evidence that load-induced mTOR activation and contractile
dysfunction is mediated by G6P, as well.
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My mechanistic studies ex vivo stemmed from our observations made in mice
subjected to an increase in workload in vivo. Compared to hearts from sham-operated
mice, hearts from banded mice demonstrated enhanced glucose uptake, G6P
accumulation, mTOR activation and contractile dysfunction one day after TAC prior to
the presence of structural changes. When increased workload was sustained via TAC for
up to 4 weeks, increasing cardiac hypertrophy (assessed by our collaborators with
cardiac MRI and confirmed by us with HW/BW measurements) directly correlated with
continued increases in FDG retention and G6P accumulation, which suggested that
metabolic remodeling precedes and potentially triggers and sustains structural
remodeling of the heart.
Previous studies have largely ignored whether cardiac substrate metabolism can
regulate ‘load-induced’ hypertrophy and contractile dysfunction (Shioi, McMullen et al.
2003; McMullen, Sherwood et al. 2004; Zhang, Contu et al. 2010). In order to address
this issue I utilized the isolated working heart model. The isolated working rat heart
allows a dynamic minute-by-minute assessment of metabolism and function and permits
us to assess intracellular metabolite concentrations and activation of the major regulatory
proteins along the mTOR signaling cascade at the end of the perfusion. The ex vivo
isolated working heart model also provided us complete control over workload, substrate
concentration and hormone supply. My findings ex vivo demonstrated that an acute
increase in workload alone is not sufficient to activate mTOR in the absence of glucose.
Only in the presence of glucose did hearts subjected to high workload demonstrate
increased phosphorylation of mTOR and its downstream targets p70S6K and 4EBP1,
suggesting that ‘load-induced’ hypertrophic signaling through mTORC1 is in fact
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substrate-dependent. More specifically, our data suggested mTORC1 is activated by the
metabolic signal G6P, which accumulates at increased workload when rates of glucose
uptake exceed the heart’s oxidative capacity.
TSC is the primary critical signaling node upstream of mTORC1 regulated by
differential phosphorylation on numerous TSC2 serine and threonine residues (Huang
and Manning 2008). I dissected the load and substrate-dependence of mTORC1
signaling in the heart and determined that increased workload alone triggers PI3K, Akt,
and minimal Akt-dependent phosphorylation of TSC2 at Ser939 phosphorylation, both
in the presence and absence of glucose. However, complete load-induced mTORC1
activation required not only Akt-dependent phosphorylation of TSC2 at Ser939 but also
a downregulation of AMPK-dependent phosphorylation of TSC2 at Ser1387 (Shaw,
Bardeesy et al. 2004), which occured with G6P accumulation. Indeed, AMPK activation
with metformin, both in vivo and ex vivo, prevented G6P-mediated mTOR activation at
increased workload in a dose-dependent manner.
In skeletal muscle, high levels of glucose activate mTOR in an AMPK-dependent
manner by modulating redox state (Saha, Xu et al. 2010). In the heart, the redox state
does not change with workload (Taegtmeyer 1985). Indeed, lactate levels and lactate-topyruvate ratio were unchanged in hearts perfused with glucose at high workload
indicating no significant changes in the cytosolic state, and presumably, the nuclear
redox state (NAD+-to-NADH ratio). However, like in skeletal muscle, AMPK
downregulation by glucose in the heart occurs independent of the energy state, which is
consistent with previous work that has demonstrated no change in the energy charge of
the heart with increased workload both ex vivo (Taegtmeyer 1985) (Neely, Denton et al.
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1972) and in vivo (Balaban, Kantor et al. 1986). AMPK is activated by the AMP/ATP
ratio in the heart (Young, Li et al. 2005). However, studies have also suggested that
metabolites such as long-chain fatty acids can activate AMPK without accompanying
changes in AMP and ATP levels in skeletal muscle (Clark, Carling et al. 2004).
In the genetically modified ACSL -/- mouse, which preferentially upregulates
cardiac glucose metabolism (like a heart subjected to increased workload), G6P levels
are elevated, AMPK is downregulated, mTOR signaling is activated, and hearts
hypertrophy independent of change in the AMP/ATP ratio, as well (Ellis, Mentock et al.
2011). Taken together, our studies highlight that ‘load-induced’ mTOR activation is
mediated by changes in glucose metabolism.
The two major isoforms of transporters that shuttle glucose into the
cardiomyocyte are GLUT1 (glucose transporter responsible for basal glucose transport
independent of insulin) and GLUT4 (glucose transporter responsible for insulinmediated glucose transport into the cardiomyocyte). Interestingly, hearts overexpressing
GLUT1 hypertrophy (Liao, Jain et al. 2002) as do hearts deficient in GLUT4 likely
secondary to compensatory GLUT1 overexpression (Abel, Kaulbach et al. 1999). These
data support our hypothesis that non-insulin mediated glucose uptake likely plays a
major role in mediating cardiac growth. Glucose uptake is increased in both models,
which gives indirect support to my hypothesis. Neither group assessed the role of
intermediary metabolite accumulation or mTOR activation in their models.
Enhanced glucose uptake in the heart has been associated with contractile
dysfunction and deemed ‘glucotoxic’ by increasing flux through the hexosamine
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biosynthetic pathway, dysregulating protein glycosylation, and producing reactive
oxygen species (Ren and Davidoff 1997; Modesti, Bertolozzi et al. 2005). Interestingly,
genetically modified mice that take up excess glucose but also demonstrate enhanced
glycolytic flux are, however, protected from glucotoxicity (Liao, Jain et al. 2002;
Taegtmeyer, McNulty et al. 2002). Taken together, these data support our hyopthesis
that intermediary glucose metabolite (G6P) accumulation may be imposing a metabolic
stress on the heart and contributing to contractile dysfunction in an mTOR-dependent
manner.
Rapamycin pretreatment rescued G6P-mediated cardiac dysfunction at increased
workload. Rapamycin is well known for its ability to bind and disrupt the mTOR
complexes (Yip, Murata et al. 2010). I now provide compelling evidence that its
metabolic effects on the heart may mediate its inhibition of mTOR and its downstream
targets, as well. Prolonged rapamycin treatment inhibits mTORC2 assembly, which
prevents phosphorylation of Akt (Sarbassov, Ali et al. 2006), a known regulator of
glucose uptake in the heart (Cong, Chen et al. 1997). Therefore, not surprisingly, I
observed that rapamycin administration reduced Akt phosphorylation and blunted rates
of glucose uptake at increased workload. In doing so, rapamycin prevented the mismatch
between glucose uptake and oxidation, depleted intracardiac G6P, inhibited the
phoshporylation of mTOR and its downstream targets, and improved contractile function
at high workload.
Interestingly, rapamycin improved cardiac power despite lowering rates of
myocardial glucose uptake and oxidation to levels nearly equivalent to hearts beating
against a normal workload may seem paradoxical. One may ask: how can the heart
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perform better when it is oxidizing less substrate? From an energetic perspective, the
data suggests that the increased energy requirements of hearts subjected to high
workload, which are met by the oxidation of carbohydrates, may no longer be necessary
in hearts of rats treated with rapamycin. I will expand upon the mechanism in the next
chapter. The improvement in cardiac power observed in rapamycin treated rats also
gives credence to the hypothesis that the hypertrophic process may not be necessary to
maintain systolic function in hearts subjected to increased workload (Hill, Karimi et al.
2000).
While metformin is known to improve cardiac function in murine models of
heart failure (Gundewar, Calvert et al. 2009; Yin, van der Horst et al. 2011), its ability to
alleviate contractile dysfunction in hearts subjected to increased workload has yet to be
studied. I demonstrate that when administered directly to the heart ex vivo or
systemically in vivo, metformin enhances the heart’s capacity to oxidize glucose, reduces
intracardiac G6P levels, inhibits mTOR activation and improves contractile function in a
dose-dependent manner. Therefore, I propose that like rapamycin, metformin
metabolically protects hearts subjected to increased workload and in doing so may
account for improving survival in diabetic patients with heart failure (Aguilar, Chan et
al. 2011). Whereas metformin decreases substrate supply to the heart by lowering
circulating nonesterified free fatty acids, inhibiting hepatic gluconeogenesis, improving
peripheral glucose uptake, and improving energy homeostasis (Wang, Zhang et al.
2011), insulin sensitizers, such as thiazolidinediones (TZDs) increase substrate uptake to
the insulin-responsive heart. Despite decreasing circulating free fatty acid levels, TZDs
therefore further flood the metabolically overloaded heart as we have previously
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demonstrated by measuring rates of substrate utilization in the ex vivo perfused heart
(Golfman, Wilson et al. 2005). It is possible that this contributes to explaining the
increased risk of heart failure and adverse cardiac events associated with their use
(Dormandy, Charbonnel et al. 2005) (Lincoff, Wolski et al. 2007; Graham, OuelletHellstrom et al. 2010).
Our studies also implicate a critical role for dysregulated glucose metabolism in
cardiac growth signaling in human heart failure. I observed a significant decrease in
G6P accumulation in human heart failure tissue samples after LVAD support (as was
seen in our rodent hearts treated with rapamycin and metformin). We have previously
observed a trend for decreased myocardial glycogen content in failing human hearts after
mechanical unloading (Razeghi and Taegtmeyer 2004) and more recently, proteomic
analysis has revealed an upregulation of proteins involved in glycolysis, energy, and
oxidative metabolism in LVAD supported patients (de Weger, Schipper et al. 2011).
Moreover, our finding that markers of mTOR activation are downregulated following
LVAD support is also consistent with studies by Baba et al. that reported decreased
myocyte size and decreased activity of Akt with mechanical unloading (Baba, Stypmann
et al. 2003). Taken together, these studies suggest that mechanical unloading with
LVAD may also metabolically unload the heart by promoting a re-coupling of glucose
uptake and oxidation, preventing intermediary metabolite accumulation, and conserving
energy in the failing heart in an mTOR-dependent manner. To date, no reliable marker
exists to predict which patients will benefit most from LVAD placement. Unfortunately,
in our 11 patient samples there is no data available on cardiac ejection fraction at time of
explantation. However, it is tempting to speculate that a metabolic parameter, such as
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cardiac G6P levels, could be useful in identifying which patients would benefit most
from LVAD placement. Due to the difficulty in obtaining myocardial tissue samples and
assessing substrate flux in humans, it remains difficult to more accurately assess the
effects of mechanical unloading on myocardial energetics and glucose utilization in the
heart.
In conclusion, in this chapter I have demonstrated that metabolic remodeling
precedes, triggers, and sustains structural remodeling of the heart. Specifically, I have
identified that dysregulated glucose metabolism (uptake in excess of oxidation) and
subsequent G6P accumulation mediate load-induced mTOR activation and contractile
dysfunction. Our study highlights the importance of intermediary metabolism as a rich
source of signals for cardiac growth and demonstrate the potential to reduce internal
work and improve cardiac efficiency by targeting the metabolic axis in load-induced
heart disease.
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CHAPTER 4: SUSTAINED mTOR ACTIVATION INDUCES ENDOPLASMIC
RETICULUM STRESS
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4.1 Introduction

While the previous chapter detailed the upstream metabolic regulation of ‘loadinduced’ mTOR signaling, this chapter focuses on its downstream consequences. Stated
otherwise, it seeks to answer the question: why does sustained mTOR activation lead to
contractile dysfunction both in vivo and ex vivo? Phosphorylation of mTOR and its
downstream targets triggers protein synthesis by promoting mRNA translation and
ribosomal biogenesis (Mayer and Grummt 2006) and inhibiting protein degradative
processes such as autophagy (Kroemer, Marino et al. 2010) and the ubiquitin proteasome
system (Depre, Wang et al. 2006; Depre, Powell et al. 2010).
Normal contractile function of the cardiomyocyte requires all synthesized
proteins to be properly folded (Sanbe, Osinska et al. 2005). Molecular chaperones
located in the endoplasmic reticulum (ER) ensure the proper folding of many proteins by
identifying hydrophobic segments of misfolded or unfolded proteins and refolding them
into functioning proteins. In doing so, the ER is able to prevent the formation of toxic
protein aggregates in the unstressed heart (Ron and Walter 2007). Mice expressing
mutant molecular chaperone proteins develop cardiomyopathy secondary to the
accumulation of protein aggregates (Maloyan, Osinska et al. 2009). Fortunately, with the
notable exception of cardiac amyloidosis, not many primary protein-folding disorders
have been identified. However, proteotoxicity in the stressed heart may be more
common that generally assumed and it may be metabolically regulated.

98

In the in vivo hemodynamically stressed heart, activation of mTOR drives protein
synthesis and floods the ER with unfolded and misfolded proteins beyond its protein
folding capacity leading to ER stress (Okada, Minamino et al. 2004). Histological
examination has clearly demonstrated marked development of the ER in hypertrophic
and failing hearts (Ferrans, Jones et al. 1975). I, therefore, explored whether increased
glucose uptake (and subsequent accumulation of intermediary metabolites of glucose
such as G6P) induces contractile dysfunction by generating ER stress in the stressed
heart. Contractile dysfunction in cardiac hypertrophy and heart failure has been linked to
elevated glucose uptake in numerous humans and animal models (Bishop and Altschuld
1970; Taegtmeyer and Overturf 1988; Zhang, Duncker et al. 1995) in an insulinindependent manner (Allard, Wambolt et al. 2000). However, it has yet to be studied
whether the mechanism involves dysregulated protein synthesis. In yeast, a number of
the molecular chaperones that assist in protein folding in the ER are responsive to
glucose and appropriately named glucose-regulated proteins (Groenendyk, Sreenivasaiah
et al. 2010).
The two main objectives of the experiments conducted in this chapter were to: 1)
Determining whether sustained mTOR activation leads to ER stress in the heart in a
substrate-dependent manner. 2) Identifying whether the ER stress response can be
targeted to improve contractile function in the stressed heart. Specifically, I tested the
hypothesis that signals generated by glucose metabolism impair contractile function via
mTOR-mediated ER stress in the heart. I tested this hypothesis by first assessing cardiac
power and ER stress in hearts subjected to high workload and perfused with glucose in
order to confirm that G6P-mediated mTOR activation is associated with ER stress and
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contractile dysfunction. Next, I alleviated ER stress pharmacologically by adding 4Phenylbutyrate (4PBA) to the perfusate in order to determine whether relieving ER
stress improves cardiac function despite continued G6P-mediated mTOR activation.
Lastly, I assessed whether rapamycin pretreatment can prevent ER stress and improve
cardiac function in hearts subjected to high workload. These experiments were meant to
establish changes in glucose metabolism, and subsequent G6P accumulation, as a
regulator of ER stress and contractile function in hearts subjected to high workload and
determine whether it is possible to pharmacologically prevent G6P-mediated ER stress.

4.2

Results

4.2.1

Load-induced ER Stress Requires Glucose and mTOR Activation

Because of mounting evidence that dysregulated mTOR activation induces ER
stress (Ozcan, Ozcan et al. 2008), I elucidated whether the induction of ER stress was
responsible for the decline in cardiac power in hearts perfused with glucose at high
workload. Transcription of the ER chaperones GRP78, GRP94, and ERp72 are increased
when a cell exhibits ER stress. Neither high workload with NCS nor glucose at normal
workload increased markers of ER stress (Fig. 4.1A). However, perfusion at high
workload with glucose as the only substrate induced a 1.9-fold increase in GRP78, 1.8fold increase in GRP94, and a 1.6-fold increase in ERP72 mRNA expression compared
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to hearts perfused with NCS at normal workload (Fig. 4.1A). It was also associated with
an increase in GRP78 protein level (Fig. 4.1B). Because prolonged ER stress causes
cellular damage and induces apoptosis I also assessed levels of GADD153/CHOP, a
marker of ER-associated apoptosis. GADD153/CHOP protein levels were unchanged
under all untreated conditions suggesting the absence of apoptosis (Fig. 4.1B). I used
thapsigargin as a positive control for ER stress. Thapsigargin is a non-competitive
inhibitor of SERCA2a (sarco-endoplasmic reticulum calcium ATP-ase) that raises
cytosolic calcium and inhibits the fusion of autophagosomes with lysosomes.
Besides for unfolded and misfolded proteins, ischemia is a known trigger of the
ER stress response. In order to determine whether ischemia was contributing to the
imposition of ER stress in hearts perfused with glucose at high workload, I assessed
lactate release. Lactate release did not significantly change with high workload or with
rapamycin treatment (Fig 4.2).
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Figure 4.1 Hearts perfused with glucose at high workload show evidence for ER
stress. (A) qRT-PCR analysis of ER stress markers in isolated working rat hearts.
Data is presented as fold change in ER stress markers compared to hearts perfused
with NCS at normal workload. Hearts perfused with glucose at high workload
undergo a nearly two-fold increase in markers of ER stress. (B) Representative
western blots demonstrate increased GRP78 protein level in hearts perfused with
glucose at high workload. n=5-8, *p<0.05 compared to hearts perfused with NCS at
normal high workload and glucose at normal workload
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Figure 4.2 Lactate release is unchanged with workload or rapamycin treatment
in isolated working hearts perfused with glucose. Lactate release was assessed in
coronary effluent samples drawn every 5 minutes throughout the perfusion. Data are
presented as mean ± SEM under each condition. n=5-8 for each group
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4.2.2

Pretreatment with Rapamycin or Metformin Inhibits ER Stress and Prevent

Contractile Dysfunction at High Workload

In order to determine whether ER stress was a consequence of mTOR activation,
I assessed markers of ER stress in hearts of animals treated with either AMPK-activator
metformin or mTOR-inhibitor rapamycin prior to being perfused with glucose at high
workload. Increases in GRP78, GRP94, ERp72 mRNA expression and GRP78 protein
level were prevented in hearts subjected to high workload in animals pretreated with
rapamycin or metformin treatment prior to perfusion (Fig. 4.3A-B).
To determine whether ER stress contributed to the decline in cardiac power in
hearts perfused with glucose at increased workload, perfusions were repeated in the
presence of the ER stress-relieving agent phenylbutyrate (PBA). PBA reduced mRNA
expression levels of GRP78, GRP94, and ERp72 (Fig. 4.3A), reduced protein level of
GRP78 (Fig. 4.3B), and was associated with a 27% increase in cardiac power in hearts
perfused at increased workload with glucose (Fig. 4.3C). Taken together, these data
suggest that ER stress is, at least partially responsible for the decline in contractile
function associated with G6P-mediated mTOR activation. PBA had no effect on cardiac
power at normal workload. PBA also had no effect on G6P accumulation, mTOR or
p70S6K phosphorylation (Fig. 4.3D). Hearts perfused at normal workload with ER
stress inducing agent thapsigargin, an inhibitor of SERCA2a, were used as a positive
control.
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Figure 4.3 ER Stress is relieved with rapamyin, metformin, and PBA. Relief of ER
stress improves contractile function in hearts perfused with glucose at high workload.
(A) qRT-PCR analysis of ER stress in isolated working rat hearts. Data is presented as fold
change in ER stress markers compared to hearts perfused with NCS at normal workload.
Hearts perfused with glucose at high workload undergo a nearly two-fold increase in markers
of ER stress, which is alleviated by rapamycin, metformin, and phenylbutyrate (PBA). (B)
Representative western blots demonstrate an inhibition of mTOR signaling and GRP78
protein level in hearts treated with rapamycin or metformin. Hearts treated directly with ER
stress reliever PBA exhibited a decrease in GRP78 protein level independent of changes in
mTOR signaling. Taken together, these data suggest that the induction of ER stress is
downstream of mTOR activation and prevented by rapamycin and metformin treatment. (C)
Cardiac power in the isolated working rat heart perfused with glucose in the presence and
absence of PBA. PBA improved cardiac power at high workload. (D) G6P accumulation in
isolated working rat hearts freeze clamped at the end of the perfusion protocol. n=5-8. Data
are presented as mean ± SEM * p< 0.05
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Next we performed microarray analyses to delineate whether systemic
pretreatment with either rapamycin or metformin or phenylbutyrate addition to the
perfusion medium could transcriptionally activate other genes responsible for contractile
function in stressed hearts perfused with glucose. Cluster analysis showed no significant
clusters of genes similarly regulated by all three treatment groups (Fig. 4.4A). The
number of genes differentially regulated by each treatment group are listed in Fig. 4.4B
and the fold-change of the four genes downregulated by each of the three treatments is
listed in Fig. 4.4C. One gene has yet to be identified and the other three genes (Scgb1a1,
Sp6, and Bpifa1) are not known to be associated with any changes in glucose
metabolism or protein turnover. Scgb1a1, the gene that encodes uteroglobin, has no
physiological role known in either rodents or humans and is named for its role in binding
progesterone in uterus of rabbits. Sp6 encodes a transcription factor with no known role
in the heart. The Bpifa1 gene is expressed in the nasopharynx during the inflammatory
response. Although this approach does not capture potential changes in changes that
could occur at the post-translational level with all three treatments, these results support
the hypothesis that an alternative mechanism is unlikely to be responsible for improving
contractile function in stressed hearts perfused with glucose.
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Figure 4.4 Transcriptome analysis of stressed hearts treated with rapamycin,
metformin, and phenylbutyrate (A) Representative heat map of microarray analyses of
rat hearts treated with rapamycin, metformin, or phenylbutyrate prior to being perfused
with glucose at high workload (B) Venn diagram of the number of genes identified that
are differentially regulated by each treatment. (C) Genes regulated by phenylbutyrate,
metformin, and rapamycin treatment. Scgb1a1 (Secretoglobin, family 1A, member 1
(uteroglobin)), Sp6 (Sp6 transcription factor), Bpifa1 (BPI fold containing family A,
member 1) n=3 rats per group. Rapa, pretreated with rapamycin; METFMN, pretreated
with metformin; PHNYLBUT, phenylbutryrate added to the perfusion medium.
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4.2.3

Markers of ER Stress are Downregulated in Failing Human Hearts

Following Mechanical Unloading with LVAD

In order to investigate whether changes in cardiac glucose metabolism were
accompanied by changes in ER stress, ER chaperones GRP78, GRP94, and ERp72 were
assessed. Protein levels of GRP78, GRP94, and ERp72 were decreased after mechanical
unloading with LVAD in the same group of patients described before (Fig. 4.4).

Figure 4.5. Mechanically unloading failing human hearts reduces
markers of ER stress. Representative western blots demonstrate a
reduction in markers of ER stress (ERP72, GRP94, GRP78) in failing
human hearts after mechanical unloading, as well. n=11 paired samples.
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4.2.4

Role of Autophagy in G6P-mediated mTOR activation

Protein quality control is highly regulated by autophagy in an mTOR-dependent
manner. I therefore wanted to know the whether markers of autophagy were dynamically
regulated with acute changes in workload and whether pretreatment with rapamycin
could prevent these changes. At the protein level, no changes were appreciated in hearts
of animals treated with rapamycin treatment prior to perfusion at high workload with
glucose (Fig. 4.6). The autophagic process is very time-dependent and an assessment of
LC3 localization into discrete punctate cytoplasmic dots (seen by immunofluoresence)
or protein levels of LCIII and Beclin at earlier and later time-points would be necessary
to confirm whether or not autophagy is regulated by glucose-dependent mTOR
activation.

Figure 4.6 Markers of autophagy are unchanged with rapamycin treatment in
hearts stressed with an acute increase in workload. Markers of autophagy (LC3,
Beclin) were unchanged by rapamycin treatment prior to being subjected to high
workload in ex vivo isolated working hearts as described in Table 2.2. NCS refers to
hearts perfused with the non-carbohydrate substrates acetoacetate (7.5 mM) and
propionate (5 mM), glucose refers to the hearts perfused with glucose as the only
substrate.
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4.3

Discussion

In hearts subjected to high workload, mTOR activation is associated with
cardiac hypertrophy and contractile dysfunction (Shioi, McMullen et al. 2003). Even in
Drosophila, dTOR (drosophila TOR) overactivity is associated with cardiac dysfunction
and decreased lifespan (Topisirovic and Sonenberg 2010). Sustained mTOR activation
synthesizes proteins beyond the folding capacity of the endoplasmic reticulum (ER), and
induces ER stress (Glembotski 2008). By evaluating the ER chaperone expression as a
marker of ER stress, I demonstrate that load-induced ER stress in the heart is
metabolically regulated. Transcriptional activation of genes regulating the ER stress
response is significantly increased in hearts subjected to high workload only when
perfused with glucose (which leads to G6P accumulation and contractile dysfunction).
Although the mechanism by which ER stress causes contractile dysfunction has yet to be
defined, I suspect that it involves a perturbation of normal calcium handling. Contractile
dysfunction in isolated rodent hearts perfused with high concentrations of glucose is
associated with the presence of abnormal calcium transients (Tang, Cheng et al. 2010).
Because the ER regulates calcium flux and excitation-contraction coupling, it is
conceivable that G6P-mediated ER stress is responsible for impairing contractile
function by inducing abnormal calcium transients. Specifically, I suggest a critical role
for ER chaperone GRP78, which is involved in calcium transport from the ER to the
mitochondria (Dudek, Benedix et al. 2009). In our studies, GRP78 gene expression and
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protein levels were dynamically upregulated with even an acute increase in workload for
30 min in the presence of glucose. Direct relief of ER stress with chemical chaperone
PBA rescued contractile function in hearts perfused with glucose at high workload. PBA
is already approved by the U.S. Food and Drug Administration for urea cycle disorders
and safely used in clinical trials to treat cystic fibrosis (Rubenstein and Zeitlin 1998). It
may have therapeutic benefit in load-induced heart disease, as well.
Rapamycin pretreatment also rescues G6P-mediated ER stress and cardiac
dysfunction at increased workload. By blunting rates of glucose uptake at increased
workload and preventing the mismatch between glucose uptake and oxidation, it
depletes intracardiac G6P, inhibits mTOR, and prevents the imposition of ER stress.
However, rapamycin treatment also improves cardiac power despite lowering
rates of myocardial glucose uptake and oxidation to unstressed levels. From an energetic
perspective, this suggests that the increased energy requirements of hearts subjected to
high workload, which are met by the oxidation of carbohydrates, may largely be
responsible for fueling protein turnover and protein quality control (“internal work”).
Protein turnover utilizes roughly 15-20% of a cell’s energy in the resting state (Waterlow
1984), and at least 3 times more energy during times of growth (Laurent and Millward
1980) (Lane and Martin 2010). It is, therefore, tempting to speculate that the energy
conserved by rapamycin’s inhibition of protein synthesis and ER stress improves cardiac
efficiency and contributes to its ability to reverse load-induced cardiac dysfunction
(Shioi, McMullen et al. 2003; McMullen, Sherwood et al. 2004; Marin, Keith et al.
2011). Furthermore, the improvement in cardiac power observed in rapamycin treated
rats gives credence to the hypothesis that the hypertrophic process may not be necessary
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to maintain systolic function in hearts subjected to increased workload (Hill, Karimi et
al. 2000). Our results offer a new perspective on the energy cost of protein synthesis and
protein quality control.
Metformin has been shown to inhibit ER stress in isolated mouse aortas from
mice fed an athrogenic diet (Dong, Zhang et al. 2010) and in cardiomyocytes subjected
to ER stress by reperfusion after hypoxia (Yeh, Chen et al. 2010). While metformin is
known to improve cardiac function in murine models of heart failure (Gundewar, Calvert
et al. 2009; Yin, van der Horst et al. 2011) its ability to alleviate ER stress in hearts
subjected to increased workload has yet to be studied. I demonstrate that metformin
inhibits G6P-mediated mTOR activation in a dose-dependent manner and protects
against load-induced ER stress.

When administered systemically, metformin also

improves the oxidative capacity of the heart, blunts G6P accumulation, and improves
cardiac function. Therefore, I propose that like rapamycin, metformin metabolically
protects hearts subjected to increased workload and in doing so may account for
improving survival in diabetic patients with heart failure (Aguilar, Chan et al. 2011).
Indeed, markers of ER stress are upregulated in failing human hearts (Okada,
Minamino et al. 2004). I now report that in hearts from a cohort of 11 non-diabetic
patients with idiopathic heart failure, mechanical unloading with an LVAD reduces
intracardiac G6P levels and protein levels of ER stress markers. Our studies in the rodent
heart implicate a critical role for dysregulated glucose metabolism and toxic
intermediary metabolite accumulation in the induction of ER stress. Similarly, I
observed a significant decrease in G6P accumulation after LVAD support. We have
previously observed a trend for decreased myocardial glycogen content in failing human
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hearts after mechanical unloading (Razeghi and Taegtmeyer 2004) and more recently,
proteomic analysis has revealed an upregulation of proteins involved in glycolysis,
energy, and oxidative metabolism in LVAD supported patients (de Weger, Schipper et
al. 2011). Taken together, these studies support our findings and suggest that mechanical
unloading promotes a re-coupling of glucose uptake and oxidation, prevents
intermediary metabolite accumulation, and conserves energy in the failing heart by
reducing ER stress. Due to the difficulty in obtaining myocardial tissue samples and
assessing substrate flux in humans, it remains difficult to more accurately assess the
effects of mechanical unloading on myocardial energetics and glucose utilization in the
heart.
When supplied with excess substrate by high fat feeding, mice become insulin
resistant and skeletal muscle, liver and adipocytes all undergo ER stress (Li, Huang et al.
2012) (Gregor and Hotamisligil 2007; Deldicque, Cani et al. 2010). Oral administration
of ER stress relieving agent 4-phenyl butyric acid (PBA) to obese mice restores systemic
insulin sensitivity, normalizes serum glucose levels, resolves fatty liver disease, and
enhances insulin action in liver, muscle, and adipose tissues (Ozcan, Yilmaz et al. 2006).
Taken together, these data support our conclusions that excess substrate supply may lead
to cellular dysfunction by inducing ER stress. Moreover, direct relief of ER stress may
have therapeutic potential both systemically and in the heart (Engin and Hotamisligil
2010). Interestingly, FDA-approved tyrosine kinase inhibitors imatinib and sunitinib
have recently been found to have ER stress relieving properties, as well, and both have
prevented and reversed obese mice from developing diabetes and heart failure (Louvet,
Szot et al. 2008; Han, Lerner et al. 2009).
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In a cohort of 11 morbidly obese patients (BMI 51.3 ± 3.0 kg/m2), markers of ER
stress were elevated in both adipose tissue and liver. Moreover, one year after gastric
bypass surgery (which forces caloric restriction and a significant reduction in exogenous
fuel supply to the body), markers of ER stress such as GRP78 were reduced in adipose
tissue and liver, which directly correlated with reversal of insulin resistance (Gregor,
Yang et al. 2009). In the heart, both diet-induced weight loss and weight-loss surgery
lead to a reduction in left ventricular mass, regression of cardiac hypertrophy, and
improvement in midwall fractional shortening (Rider, Francis et al. 2009; Algahim, Lux
et al. 2010; Owan, Avelar et al. 2011). By reducing substrate supply to the heart, it is
plausible that the beneficial cardiovascular effects may be mediated by regulating
glucose metabolism, mTOR activation, and ER stress in the heart.

4.4

Limitations

I am the first to admit that my studies are not without limitations. First, there are
significant differences between the human and rodent heart that are worth mentioning.
The human heart rate and ejection fraction is significantly less than that of the rodent
heart. Also, acute increases in workload via aortic banding in vivo or doubling afterload
ex vivo may not accurately mimic the chronic, low levels of hemodynamic stress induced
by pathological stimuli that induce cardiac hypertrophy. Moreover, while it is plausible
that abnormal calcium handling by the sarcoplasmic reticulum may be responsible for
ER stress induced contractile dysfunction in the rodent heart, it is less clear whether the
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same mechanism would exist in the human heart. Calicum handling in rodents relies
much more heavily on transport through the sarcoplasmic reticulum than the human
heart, which seems to rely more heavily on transsarcolemmal calcium transport (Berenji,
Drazner et al. 2005). In spite of these limitations and because the structural, functional,
and metabolic changes that occur in the rodent heart mimic those of the human heart, I
believe the work in this dissertation has identified glucose metabolism (and specifically
glucose 6-phosphate) as a dynamic regulator of myocardial protein synthesis, ER stress
and possibly also protein turnover as well as expanded the role of energy substrate
metabolism from simply being a provider of ATP to a regulator of cardiac protein
synthesis and growth as well.
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SUMMARY OF RESULTS AND PERSPECTIVE
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The heart is a dynamic organ with an enormous capacity to respond to stress. The
heart also remodels metabolically and structurally before it goes into heart failure. The
question I began to address in my dissertation tried to fill an important gap in the current
knowledge of cardiac physiology: Does the early metabolic remodeling process regulate
the structural and functional remodeling process in the heart? In a series of different
experimental strategies I provided evidence in support of our hypothesis that metabolic
remodeling (which is potentially reversible) regulates functional and structural
remodeling (which is largely irreversible) and discovered that it is both deleterious and
preventable.
With help from collaborators at the University of Virginia, we first quantitatively
demonstrated in vivo that enhanced glucose uptake in the heart accompanies loadinduced contractile dysfunction prior to the presence of structural changes. Stated
otherwise, metabolic remodeling precedes structural remodeling of the heart and
accompanies load-induced contractile dysfunction. Before beginning my dissertation
project, numerous studies had quite convincingly provided evidence that load-induced
mTOR signaling mediates cardiac growth (Shioi, McMullen et al. 2003; McMullen,
Sherwood et al. 2004; Zhang, Contu et al. 2010). However, every study largely ignored
the fact that changes in workload are accompanied by instantaneous changes in cardiac
substrate metabolism (Goodwin, Taylor et al. 1998), which could be contributing to
regulating ‘load-induced’ hypertrophy and contractile dysfunction as well. Indeed, my
findings in the isolated working heart ex vivo demonstrate that an acute increase in
workload is not sufficient to activate mTOR in the absence of glucose, suggesting that
‘load-induced’ hypertrophic signaling through mTORC1 is glucose-dependent. A
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number of genetically engineered mouse hearts that take up glucose in excess of its
oxidative capacity also hypertrophy and provide evidence in support of our hypothesis,
as well (Domenighetti, Danes et al. 2010; Ellis, Mentock et al. 2011; Liu, Yu et al.
2011).
More specifically, I propose that mTORC1 is activated by the metabolic signal
G6P. I dissected the load and substrate-dependence of mTORC1 signaling in the heart ex
vivo and determined that doubling the workload alone triggers PI3K, Akt, and minimal
Akt-dependent phosphorylation of TSC2 at Ser939 phosphorylation, both in the presence
and absence of glucose. However, complete ‘load-induced’ mTORC1 activation and
contractile dysfunction requires not only Akt-dependent phosphorylation of TSC2 at
Ser939 but also a downregulation of AMPK-dependent phosphorylation of TSC2 at
Ser1387 (Shaw, Bardeesy et al. 2004), which occurs with G6P accumulation (in hearts
perfused with glucose as the only substrate at high workload).
In order to determine the consequences of G6P-dependent mTOR activation, I
focused my attention on the role of endoplasmic retiticulum (ER) stress. When subjected
to hemodynamic stress (continued pumping against high workload), increased rates of
protein synthesis flood the ER with unfolded and misfolded proteins beyond its capacity
to cope with the load, which leads to ER stress (Glembotski 2008). Whether increased
glucose uptake and accumulation as G6P causes contractile dysfunction by generating
ER stress remains unknown. I therefore investigated whether when subjected to high
workload, the metabolic remodeling process (increased reliance upon glucose)
contributes to a decline in cardiac function by generating ER stress.
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Indeed, it does. Expression levels of three early response markers of ER stress
(GRP78, ERp72, and GRP94) all correlated with G6P-mediated mTOR activation and
contractile dysfunction ex vivo. Furthermore, both rapamycin and metformin
pretreatment, which inhibited G6P-mediated mTOR activation and rescued contractile
function, also prevented the upregulation of markers of ER stress at both the
transcriptional and translational level. Similarly, pharmacologic alleviation of ER stress
with chemical chaperone 4-Phenylbutyrate (4PBA) improved cardiac function, as well.
Alleviation of ER stress improved contractile function despite elevated G6P levels,
however, suggesting that the induction of ER stress is downstream of G6P-mediated
mTOR activation. Taken together, these data suggested that G6P-mediated mTOR
activation leads to ER stress and impairs contractile function in hearts subjected to high
workload.
I believe my findings also shed new light on the energetic cost of protein
turnover in the stressed heart. Rather unexpectedly, rapamycin treatment improved
cardiac power despite lowering rates of myocardial glucose uptake and oxidation to
unstressed levels. From an energetic perspective, this suggests that the increased energy
requirements of hearts subjected to high workload, which are met by the oxidation of
carbohydrates, may largely be responsible for fueling protein turnover and protein
quality control (“internal work”). Protein turnover utilizes roughly 15-20% of a cell’s
energy in the resting state (Waterlow 1984), and at least 3 times more energy during
times of growth (Laurent and Millward 1980). It is, therefore, tempting to speculate that
the energy conserved by rapamycin’s inhibition of protein synthesis and ER stress
improves cardiac efficiency and contributes to its ability to reverse load-induced cardiac
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dysfunction (Shioi, McMullen et al. 2003; Sancak, Peterson et al. 2008; Marin, Keith et
al. 2011). Furthermore, the improvement in cardiac power observed in rapamycin treated
rats gives credence to the hypothesis that the hypertrophic process may not be necessary
to maintain systolic function in hearts subjected to increased workload (Hill, Karimi et
al. 2000). Our results offer a new perspective on the energy cost of protein synthesis and
protein quality control.
My studies have also demonstrated a novel mechanism that contributes to the
improvement in contractile function known to occur in the stressed heart with metformin
treatment. Metformin has been shown to inhibit ER stress in isolated mouse aortas from
mice fed an athrogenic diet (Dong, Zhang et al. 2010) and in cardiomyocytes subjected
to ER stress by reperfusion after hypoxia (Yeh, Chen et al. 2010). While metformin is
known to improve cardiac function in murine models of heart failure (Gundewar, Calvert
et al. 2009; Yin, van der Horst et al. 2011), its ability to alleviate ER stress in hearts
subjected to increased workload had previously not been studied. I demonstrate that
metformin inhibits G6P-mediated mTOR activation in a dose-dependent manner and
protects against load-induced ER stress. When administered systemically, metformin
also improves the oxidative capacity of the heart, blunts G6P accumulation, and
improves cardiac function. Therefore, I propose that like rapamycin, metformin
metabolically protects hearts subjected to increased workload and in doing so may
account for improved survival in diabetic patients with heart failure (Aguilar, Chan et al.
2011). These data may have wide implications outside of cardiovascular disease, as well.
Metformin is associated with increased survival in various types of cancer although the
mechanism remains unknown (Dowling, Goodwin, et al. 2011). Its well-studied effects
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of activating AMPK, reducing plasma insulin levels, and inhibiting hepatic
gluconeogenesis likely reduce G6P accumulation and subsequent mTOR activation.
Next, one must consider the possible clinical relevance of my findings. Despite
the recent advances in cardiovascular medicine, the majority of patients with heart
disease still progress to end-stage heart failure, for which treatment is largely limited to
cardiac transplantation. As the need for transplantable hearts continues to far exceed the
supply of available organs, left ventricular assist devices (LVADs) are implanted with
increased frequency. Although initially meant to serve as a ‘bridge to transplantation’,
and not necessarily as destination therapy, many patients experienced functional
improvement without requiring a heart transplantation but the mechanism remains
largely unknown. Transcriptional analysis of metabolic genes revealed a reversal of the
failing human heart to the fetal gene program (Razeghi, Young et al. 2001) and a partial
reversal after implantation of an LVAD (Razeghi, Young et al. 2002). However,
proteomic analysis has now shown an upregulation of proteins involved in glycolysis,
energy, and oxidative metabolism in LVAD supported patients (de Weger, Schipper et
al. 2011). Taken together, these data suggest improved metabolic capacity with LVAD
implantation. Both the mTOR signaling pathway and markers of ER stress are also
upregulated in the hypertrophied and failing human heart. I have found that in hearts
from a cohort of 11 patients with idiopathic heart failure, mechanical unloading with a
left ventricular assist device (LVAD) reduces protein levels of ER stress markers.
Moreover, consistent with our data that implicate a critical role for dysregulated glucose
metabolism and intermediary metabolite accumulation in the induction of ER stress, I
observed a significant decrease in G6P accumulation after LVAD support. These studies
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suggest that mechanical unloading may promote a re-coupling of rates of glucose uptake
and oxidation prevent intermediary metabolite accumulation and contribute to a
reduction of ER stress in the failing heart.
However, a number of important questions remain. This is a common feature of
all novel research. The first question is: What is the exact molecular mechanism by
which G6P modulates TSC2 to promote mTOR activation? Two probable mechanisms
by which G6P may regulate TSC2 include: 1) modulation of one or several kinases that
act on TSC2 or 2) allosteric regulation of TSC2 itself. The generation and transfection
into of constructs containing mutated phosphorylation sites into stressed cardiomyocytes
would help determine whether G6P modulates TSC2 or one of its upstream kinases.
Phosphorylation site mutations on TSC2 have been used previously to investigate
mTORC1 activation (Huang and Manning 2008). It is plausible that G6P promotes the
phosphorylation of TSC2 or one of its upstream kinases in a manner similar to its ability
to control the phosphorylation state of glycogen synthase (Huang, Wilson et al. 1997).
Radiolabeled binding assays can determine whether G6P promotes mTOR activation by
directly binding itself to TSC2 or one of its upstream kinases by pulling down the
candidate kinases from rat heart lysates by immunoprecipitation, incubating with
uniformly labeled [14C]-G6P, and assaying for radioactivity. This approach has
previously been used to identify novel binding of proteins in the Akt/mTOR pathway to
small non-protein molecules such as microfilaments (Zhu, Rosenblatt et al. 2011).
The second question is: By which mechanism does ER stress causes contractile
dysfunction? I suspect the mechanism involves a perturbation of proper calcium cycling
in and out of the cardiomyocytes specialized ER, the sarcoendoplasmic (SR) reticulum.
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The SR is a known regulator of calcium flux and excitation-contraction coupling in the
cardiomyocyte. Indeed, contractile dysfunction in rodent hearts perfused with high
concentrations of glucose has already been associated with the presence of abnormal
calcium (Hu, Belke et al. 2005). It is conceivable that this may have been mediated by
ER stress. Moreover, mice with cardiac overexpression of the SR Ca2+ transporter
(sarco/endoplasmic reticulum Ca2+-ATPase, SERCA) demonstrate improved cardiac
function compared to wild type mice when subjected to aortic banding (Suarez, Gloss et
al. 2004). Assessing glucose metabolism, mTOR activation, and markers of ER stress in
these mice would help determine the exact mechanism by which ER stress induces
contractile dysfunction in hearts subjected to high workload.
The third question is: How can the new knowledge on a metabolic signal driving
another signaling pathway be leveraged to devise new therapeutic targets for the
treatment of heart failure. This is perhaps the most challenging question for a young
physician-scientist. The metabolic management of heart failure is the subject of reviews
(Osterholt, Sen et al. 2012), clinical studies(Wallhaus, Taylor et al. 2001), and of metaanalyses (Zhang, Lu et al. 2012). It is my hope that my work has laid the cornerstone for
a new paradigm, just as Rudolph Schoenheimer wrote when he discovered the dynamic
state of body constituents (Schoenheimer, 1942): “The new results imply that not only
the fuel, but also the structural materials are in a steady state of flux. The classical
picture must thus be replaced by one which takes account of the dynamic state of body
structure” (page 64).
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Conclusion
My findings demonstrate that metabolic remodeling precedes, triggers, and
sustains structural remodeling of the heart. Specifically, I identify dysregulated
glycolytic homeostasis as a novel regulator of contractile function, mTOR activation,
and ER stress in response to increased cardiac workload. The study highlights the
importance of intermediary metabolism, not only as energy providing substrates, but also
as signals for driving cardiac growth. In doing so, it underscores the need to better
metabolically protect patients with heart failure and sheds light on the metabolic effects
of mechanically unloading the failing human heart. I believe these results have wideranging implications for load-induced heart disease and based on the new findings, I
speculate that targeting metabolism offers therapeutic promise in treating cardiovascular
disease.
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